STATUTORY INSTRUMENTS

1997 No. 1830

MEDICINES

The Prescription Only Medicines (Human Use) Order 1997

Made	25th July 1997
Laid before Parliament	28th July 1997
Coming into force	18th August 1997

The Secretary of State concerned with health in England, the Secretaries of State concerned with health and with agriculture in Wales and in Scotland respectively, the Minister of Agriculture, Fisheries and Food, the Department of Health and Social Services for Northern Ireland and the Department of Agriculture for Northern Ireland, acting jointly, in exercise of powers conferred on them by sections 58(1), (4) and (5), 59(1) and 129(4) of the Medicines Act 1968(1) or, as the case may be, those conferred by the said provisions and now vested in them(2), and of all other powers enabling them in that behalf, after consulting such organisations as appear to them to be representative of interests likely to be substantially affected by this Order, pursuant to section 129(6) of that Act, and after consulting and taking into account the advice of the Medicines Commission pursuant to sections 58(6) and 129(7) of that Act, hereby make the following Order:

Citation, commencement and interpretation

1.—(1) This Order may be cited as the Prescription Only Medicines (Human Use) Order 1997 and shall come into force on 18th August 1997.

(2) In this Order, unless the context otherwise requires-

F1
F1
F1
F1
F1

^{(1) 1968} c. 67. Section 58 has been amended by the Prescription by Nurses Etc. Act 1992 (c. 28), section 1. The expression "the appropriate Ministers" is defined in section 1(2) of the Medicines Act 1968.

⁽²⁾ In the case of the Secretaries of State concerned with health in England and in Wales by virtue of article 2(2) of, and Schedule 1 to, the Transfer of Functions (Wales) Order 1969 (S.I. 1969/388); in the case of the Secretary of State concerned with Agriculture in Wales by virtue of article 2(3) of, and Schedule 1 to, the Transfer of Functions (Wales) (No. 1) Order 1978 (S.I. 1978/272) and in the case of the Northern Ireland Departments by virtue of section 40 of, and Schedule 5 to, the Northern Ireland Constitution Act 1973 (c. 36) and section 1(3) of, and paragraph 2(1)(b) of Schedule 1 to, the Northern Ireland Act 1974 (c. 28).

F2
F1
F3
F1
F4
F5
F1
F6
F1
"inhaler" does not include an aerosol;
F1
"maximum strength" means-
(a) the maximum quantity of a substance by weight or volume contained in a dosage unit of a medicinal product;

- (b) the maximum percentage of a substance contained in a medicinal product calculated in any of the following ways-
 - (i) weight in weight,
 - (ii) weight in volume,

- (iii) volume in weight, or
- (iv) volume in volume,

and if the maximum percentage calculated in those ways differs, the higher or highest such percentage;

- F1...
- F1

F1...

- F1
- ... F1
- ...
- F1
- F1
- F1
- F1
- F1
- F1
- •••
- F1 ...
- F1 ...
- F1 ...
- F1
- F1 ...
- F1 ...
- F1
- F1
- ...
- F1 ...
- F1 ...
- F1
- F1
- F1
- ...
- F1 ...
- F1 ...
- F1 ...
- F1
- F1
- F1
- ...
- F1
- F1 ...

F1 F1

[^{F8}(2A) In this Order, unless the context otherwise requires, any expression defined by any provision of the Human Medicines Regulations 2012 has the same meaning as it has for the purposes of those Regulations.]

(3) For the purposes of this Order, the equivalence of a substance to a reference material shall be determined by calculating the amount of that reference material which is contained in that substance either by weight or, where the amount of the reference material is specified in terms of international units of activity, those units.

(4) In this Order, unless the context otherwise requires, a reference-

- (a) to a numbered section is to the section of the Act which bears that number,
- (b) to a numbered article or Schedule is to the article of, or Schedule to, this Order which bears that number,
- (c) in an article or in a Part of a Schedule to a numbered paragraph is to the paragraph of that article or Part of that Schedule which bears that number, and
- (d) in a paragraph to a lettered sub-paragraph is to the sub-paragraph of that paragraph which bears that letter.
- (5) In [^{F9}Schedules 1 and 2]-
 - (a) entries specified in columns 2 to 5 relate to the substances listed in column 1 against which they appear and where, in relation to a particular substance listed in column 1, an entry in columns 2 to 5 bears a number or letter it relates only to such entries in the other of those columns as bear the same number or letter;
 - (b) the following abbreviations are used:

"g" for gram,

"iu" for international unit of activity,

"mcg" for microgram,

"mg" for milligram,

"ml" for millilitre.

^{F10}(6)

- ^{F10}(7)
- ^{F10}(8)
- ^{F10}(9)

Textual Amendments

- Words in art. 1(2) omitted (14.8.2012) by virtue of The Human Medicines Regulations 2012 (S.I. F1 2012/1916), reg. 1(2), Sch. 34 para. 71(2)(a) (with Sch. 32)
- F2 Words in art. 1 omitted (1.4.2002) by virtue of The Prescription Only Medicines (Human Use) Amendment Order 2002 (S.I. 2002/549), arts. 1(1), 2(2)(a)
- F3 Words in art. 1(2) omitted (1.5.2006) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2006 (S.I. 2006/915), arts. 1(1), 2(b)
- F4 Words in art. 1(2) omitted (1.5.2006) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2006 (S.I. 2006/915), arts. 1(1), 2(c)
- F5 Words in art. 1(2) omitted (1.5.2006) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2006 (S.I. 2006/915), arts. 1(1), 2(d)
- F6 Words in art. 1(2) omitted (1.5.2006) by virtue of The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2006 (S.I. 2006/915), arts. 1(1), 2(e)
- F7 Words in art. 1 omitted (9.7.2003) by virtue of The Health Professions Order 2001 (Consequential Amendments) Order 2003 (S.I. 2003/1590), art. 1, Sch. para. 21(2)(b)
- F8 Art. 1(2A) substituted (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 34 para. 71(2)(b) (with Sch. 32)
- F9 Words in art. 1(5) substituted (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 34 para. 71(2)(c) (with Sch. 32)
- F10 Art. 1(6)-(9) omitted (14.8.2012) by virtue of The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 34 para. 71(2)(d), Sch. 35 (with Sch. 32)

Appropriate practitioners

^{F11}2.

Textual Amendments

F11 Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Medicinal products on prescription only

Textual Amendments

Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), F11 Sch. 35 (with Sch. 32)

Prescribing and administration by nurse independent prescribers

 Textual Amendments

 F11
 Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Prescribing and administration by supplementary prescribers

Textual Amendments
F11 Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemptions from conditions in respect of the cases or circumstances in which a supplementary prescriber may administer a medicinal product

^{F11}3C.

Textual Amendments

```
    F11 Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2),
    Sch. 35 (with Sch. 32)
```

Duration of special provisions in relation to new medicinal products

Textual Amendments

F11 Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2),
 Sch. 35 (with Sch. 32)

Exempt medicinal products

5.—(1) $[^{F12}A$ medicinal product that is not the subject of a marketing authorisation is a prescription only medicine for the purposes of the Human Medicines Regulations 2012 if it, or a substance in it, is listed in column 1 of Schedule 1, unless there] –

- (a) is an entry in column 2, 3, 4 or 5 of that Schedule which contains a condition and that condition is satisfied in accordance with the following provisions of this article; or
- (b) there is more than one such condition which applies where that substance is used in that product and each of those conditions is so satisfied.

[^{F13}(1A) In paragraph (1) "marketing authorisation" means—

- (a) in relation to medicinal products for sale or supply in Great Britain, a UKMA(GB) or UKMA(UK);
- (b) in relation to medicinal products for sale or supply in Northern Ireland, a UKMA(NI) or UKMA(UK), an EU marketing authorisation or a parallel import licence.]

(2) Where a maximum strength is specified in column 2 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where the maximum strength of that substance in that medicinal product, or where specified in that column the maximum strength of a medicinal product which contains that substance, does not exceed that specified maximum or, where the medicinal product consists of more than one of the substances sodium fluoride, sodium monofluorophosphate or stannous fluoride combined in a dentifrice, where the maximum strength of that combination of substances in a product does not exceed the equivalent of 0.15 per cent of fluorine.

(3) Where a route of administration is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for administration only by that route.

(4) Where a use is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition in respect of use where it is sold or supplied only for use-

- (a) where a purpose for which it may be used is so specified, for that purpose;
- (b) where the class of persons in whom it may be used is so specified, in persons of that class $\int_{1}^{F_{14}}$,

provided that, where the entry in column 3 contains a condition to the effect that the product is to be wholly or mainly for use in a specified class of persons, the product satisfies that condition where it is sold or supplied wholly or mainly for use in persons of that class].

(5) Where a pharmaceutical form is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied in that pharmaceutical form.

(6) Where a maximum dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum dose which does not exceed that specified maximum dose.

(7) Subject to paragraph (8), where a maximum daily dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum daily dose which does not exceed that specified maximum daily dose.

(8) A medicinal product which contains more than one of the substances-

Atropine

- Atropine Methobromide
- Atropine Methonitrate

Atropine Oxide Hydrochloride

Atropine Sulphate

Hyoscine

Hyoscine Butylbromide

Hyoscine Hydrobromide

Hyoscine Methobromide

Hyoscine Methonitrate

Hyoscyamine

Hyoscyamine Hydrobromide

Hyoscyamine Sulphate,

satisfies the condition only where it is sold or supplied for use at a maximum daily dose which does not exceed 1 milligram in total of the alkaloids derived from belladonna, hyoscyamus, stramonium or other solanaceous plant which are contained in that medicinal product.

(9) Where a maximum period of use or a maximum frequency of use is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use for a maximum period or frequency, as the case may be, which does not exceed the maximum period of use or the maximum frequency of use which is so specified.

(10) Where a maximum quantity is specified in column 5 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it, or where so specified in that column, the medicinal product which contains that substance is sold or supplied in a quantity which does not exceed that specified maximum quantity.

(11) In paragraphs (2) to (7) and (9) and (10) a reference to a numbered column is a reference to the column bearing that number in Schedule 1.

Textual Amendments

- **F12** Words in art. 5(1) substituted (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), **Sch. 34 para. 71(3)** (with Sch. 32)
- F13 Art. 5(1A) inserted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 8 para. 4 (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 194(a)); 2020 c. 1, Sch. 5 para. 1(1)
- F14 Words in art. 5(4) added (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 2

Exemption for products consisting of or containing aloxiprin, aspirin or paracetamol

^{F15}5A.

Textual Amendments

F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption for products consisting of or containing pseudoephedrine salts or ephedrine base or salts

Textual Amendments

F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Circumstances in which controlled drugs and medicinal products authorized by the European Community are not prescription only medicines

```
Textual Amendments
 F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg.
       1(2), Sch. 35 (with Sch. 32)
```

Exemption for parenteral administration in an emergency to human beings of certain prescription only medicines

^{F15}7.....

Textual Amendments

```
F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg.
      1(2), Sch. 35 (with Sch. 32)
```

Exemptions for administration of smallpox vaccine

^{F15}7A.

Textual Amendments

F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption for administration by operators

Textual Amendments

F11 Arts. 2-4 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemptions for emergency sale or supply

Textual Amendments

```
F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg.
      1(2), Sch. 35 (with Sch. 32)
```

Exemption for non-parenteral administration to human beings

^{F15}9.....

Textual Amendments F15 Arts. 5A-9 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption for medicinal products at high dilutions

10.— $[^{F16}(1)]$ [F17 A medicinal product is not a prescription only medicine for the purposes of the Human Medicines Regulations 2012 by virtue of Article 5(1) if it is] a medicinal product which is not for parenteral administration and which consists of or contains, any of the substances listed in column 1 of Schedule 1 [F18 or in Schedule 2], only one or more unit preparation of such substances, if–

- (a) each such unit preparation has been diluted to at least one part in a million (6x), and the person selling, supplying or administering the medicinal product has been requested by or on behalf of a particular person and in that person's presence to use his own judgment as to the treatment required; or
- (b) each such unit preparation has been diluted to at least one part in a million million (6c).

 $[^{F19}(2)$ $[^{F17}A$ medicinal product is not a prescription only medicine for the purposes of the Human Medicines Regulations 2012 by virtue of Article 5(1) if it is] a medicinal product which is not for parenteral administration and which consists of or contains solely one or more unit preparations of the following substances—

Aconite Arsenic Trioxide Belladonna Herb Ignatia Bean Nux Vomica Seed,

if each such unit preparation has been diluted to at least one part in a million (6x)]

Textual Amendments

- F16 Art. 10 renumbered as art. 10(1) (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 9
- F17 Words in art. 10(1)(2) substituted (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 34 para. 71(4) (with Sch. 32)
- **F18** Words in art. 10(1) substituted (1.5.2006) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2006 (S.I. 2006/915), arts. 1(1), **8**
- F19 Art. 10(2) inserted (4.4.2003) by The Prescription Only Medicines (Human Use) Amendment Order 2003 (S.I. 2003/696), arts. 1(1), 9

Exemptions for certain persons

Textual Amendments

```
    F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)
```

Exemption for sale or supply in hospitals

^{F20}12.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemptions for the supply and administration of prescription only medicines by national health service bodies

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), **Sch. 35** (with Sch. 32)

Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist doctors or dentists in providing national health services

^{F20}12B.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption for persons conducting a retail pharmacy business who supply or administer prescription only medicines under a Patient Group Direction

^{F20}12C.

```
        F20
        Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)
```

Exemption for the supply and administration of prescription only medicines by independent hospitals, clinics and agencies

^{F20}12D.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist the provision of health care by or on behalf of the police, the prison services or the armed forces

^{F20}12E.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption for the supply of prescription only medicines in the event or anticipation of pandemic disease

^{F20}12F.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemption in cases involving another's default

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Exemptions relating to prescriptions given by certain health professionals

^{F20}13A.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), **Sch. 35** (with Sch. 32)

Exemption in the case of a forged prescription

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Prescriptions

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Revocations

^{F20}16.

Textual Amendments

F20 Arts. 11-16 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2), Sch. 35 (with Sch. 32)

Signed by authority of the Secretary of State for Health

Baroness Jay Minister of State, Department of Health

Win Griffiths Parliamentary Under Secretary of State, Welsh Office

Sam Galbraith Parliamentary Under Secretary of State, The Scottish Office

Jeff Rooker Minister of State, Ministry of Agriculture, Fisheries and Food Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on 22nd July 1997.



D. C. Gowdy Permanent Secretary

Sealed with the Official Seal of the Department of Agriculture for Northern Ireland on 18th July 1997.



P. Small Permanent Secretary

SCHEDULE 1

Articles 3(a), 5(1) and 10

SUBSTANCES WHICH IF INCLUDED IN MEDICINAL PRODUCTS MAKE THOSE PRODUCTS PRESCRIPTION ONLY MEDICINES AND EXEMPTIONS FROM RESTRICTIONS ON THE SALE AND SUPPLY OF PRESCRIPTION ONLY MEDICINES

		from the restri	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
[^{F21} Acampro	osate]			
Acarbose				
Acebutolol Hydrochlori	de			
[^{F21} Aceclofe	nac]			
Acemetacin				
Acetarsol				
Acetazolam	ide			
Acetazolam Sodium	ide			
Acetohexam	nide			
Acetylcholin Chloride	ne0.2 per cent	External		
Acetylcyste	ine			
Acipimox				
Aciclovir	5.0 per cent	External For treatment of herpes simplex virus infections of the lips and face (Herpes labialis)		Container or package containing not more than 2g of medicinal product
Acitretin				
Aclarubicin Hydrochlori	de			
Aconite	1.3 per cent	External		

Column 1 Column 2 Column 3 Column 4 Column 5 Substance Maximum strength Route of administration, use or pharmaceutical form Treatment limitations Maximum quantity Acrivastine 24 mg (MDD) Container or package containing not more than 240mg of Acrivastine Column 5 Maximum quantity Acrivastine 24 mg (MDD) Container or package containing not more than 240mg of Acrivastine Actinomycin D F*2 Adenosine Adrenaline (1) By inhaler F*2 (2) External (************************************		cemptions from the rest rescription only medicir		
Acrosoxacin Acrosoxacin Actinomycin C Actinomycin D [^{F22} Adapalene] Adenosine Adrenaline Adrenaline Adrenaline Adrenaline Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By inhaler (2) External (2) External (2) External (2) External (2) External (2) External (2) External (3) By (3) C (4) C (4) C (4) C (5) C (5	n 3 Column 4 of Treatment li stration,	olumn 2 Column 3 faximum Route of rength administra use or pharmaceu	in I C ince M	
Actinomycin C Actinomycin D [^{F22} Adapalene] Adenosine Adrenaline Adrenaline Adrenaline Adrenaline Adrenaline Acid Tartrate (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By inhaler (2) External (2) External (3) External (3) External (4) External (4) External (5) External (5) External (6) External (7) Extern	24 mg (MDI		stine	Acrivas
C Actinomycin D [^{F22} Adapalene] Adenosine Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By inhaler (2) External (2) External (2) External (2) External (2) External (2) External (2) External (2) External (2) External			xacin	Acroso
D [^{F22} Adapalene] Adenosine Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By Acid inhaler Tartrate (2) External (1) By inhaler (2) External (1) By inhaler (2) External (2) External			mycin	
Adenosine Adrenaline (1) By inhaler (2) External [^{F23} (except ophthalmic)] Adrenaline (1) By Acid inhaler Tartrate (2) External (2) External (2) External (2) External (2) External (2) External (2) External (2) External (2) External (3) By inhaler (3) External (4) By (5) External (5) External (6) External (7) By (7) External (7) By (7) External (7) By (7) External (7) By (7) External (7) By (7) External (7) External			mycin	
Adrenaline(1) By inhaler(2) External [^{F23} (except ophthalmic)]Adrenaline Acid(1) By inhalerTartrate(2) External(2) ExternalAdrenaline Hydrochloride(1) By inhaler(2) ExternalAdrenaline Hydrochloride(2) ExternalAdrenaline (2) External(2) ExternalAdrenaline Hydrochloride(2) External(2) External			apalene]	[^{F22} Ada
inhaler(2) External[^{F23} (except ophthalmic)]Adrenaline(1) ByAcidinhalerTartrate(2) ExternalAdrenaline(1) By inhalerHydrochloride(1) By inhaler(2) ExternalAdrenaline(1) By inhaler(2) ExternalAdrenaline(1) By inhaler(2) External			sine	Adenos
[^{Fi3} (except ophthalmic)]Adrenaline(1) ByAcidinhalerTartrate(2) ExternalAdrenaline(1) By inhalerHydrochlorideinhaler(2) ExternalAdrenocortical			line	Adrena
AcidinhalerTartrate(2) ExternalAdrenaline(1) ByHydrochlorideinhaler(2) ExternalAdrenocortical	ept	[^{F23} (except		
Adrenaline (1) By Hydrochloride inhaler (2) External (2) External			line	
Hydrochloride inhaler (2) External Adrenocortical	rnal	(2) External	e	Tartrate
Adrenocortical				
	rnal	(2) External		
Extract				Adreno Extract
Albendazole			lazole	Albend
Alclofenac			enac	Alclofe
Alclometasone Dipropionate				
Alcuronium Chloride				
Aldesleukin			eukin	Aldesle
Aldosterone			erone	Aldoste

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
[^{F21} Alendrona Sodium]	ate			
Alfacalcidol				
Alfuzosin Hydrochlorid	e			
Allergen Extracts				
Allopurinol				
Allyloestrenc	ol			
[^{F24} Aloxiprin	(1) 620 mg	(1) Non- effervescent tablets and capsules		(1) The quantity sold or supplied in one container or package shall not exceed 32
				The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100
		(2) All preparations other than non- effervescent tablets or capsules]		

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Substance I	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
Alphadolone Acetate				
Alphaxalone				
Alprenolol				
Alprenolol Hydrochloride				
Alprostadil				
Alseroxylon				
[^{F22} Altretamine]]			
Amantadine Hydrochloride				
Ambenonium Chloride				
Ambutonium Bromide				
Amcinonide				
Ametazole Hydrochloride				
Amethocaine		Non- ophthalmic use		
Amethocaine Gentisate		Non- ophthalmic use		
Amethocaine Hydrochloride		Non- ophthalmic use		
Amikacin Sulphate				
Amiloride Hydrochloride				
Aminocaproic Acid				
Aminoglutethir	nide			

Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Aminopterin Sodium					
Amiodarone Hydrochlorid	le				
Amiphenazo Hydrochloric					
[^{F25} Amisulpri	ide]				
Amitriptyline	e				
Amitriptyline Embonate	e				
Amitriptyline Hydrochloric					
Amlodipine Besylate					
Ammonium Bromide					
Amodiaquine Hydrochloric					
Amorolfine Hydrochloric	le				
Amoxapine					
Amoxycillin					
Amoxycillin Sodium					
Amoxycillin Trihydrate					
Amphomycii Calcium	n				
Amphoterici	n				
Ampicillin					
Ampicillin Sodium					
Ampicillin Trihydrate					

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
Amsacrine				
Amygdalin				
Amyl Nitrite				
Amylocaine Hydrochloride	2	Non- ophthalmic use		
[^{F21} Anastrozol	e]			
Ancrod				
Androsterone				
Angiotensin Amide				
Anistreplase				
Anterior Pituitary Extract				
Antimony Barium Tartrate				
Antimony Dimercaptosu	ccinate			
Antimony Lithium Thiomalate				
Antimony Pentasulphide				
Antimony Potassium Tartrate				
Antimony Sodium Tartrate				
Antimony Sodium Thioglycollate	2			

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity	
Antimony Sulphate					
Antimony Trichloride					
Antimony Trioxide					
Antimony Trisulphide					
Apiol					
Apomorphine	e				
Apomorphine Hydrochlorid					
[^{F22} Apracloni Hydrochlorid					
Aprotinin					
Arecoline Hydrobromic	le				
Argipressin					
Aristolochia					
Aristolochia Clematitis					
Aristolochia Contorta					
Aristolochia Debelis					
Aristolochia Fang-chi					
Aristolochia Manshuriens	is				
Aristolochia Serpentaria					
Arsenic					
Arsenic Triiodide					

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Arsenic Trioxide				
Arsphenami	ne			
[^{F26} Aspirin	[^{F27} (1) 75mg]	[^{F27} (1) Non- effervescent tablets and capsules]		IF27(1)Thequantitysoldorsuppliedinonecontainerorpackageshallnotexceed100Thequantityofnon-effervescenttablets,capsulesor acombinationofbothsold orsuppliedto apersonat anyonetimeshallnotexceed100
	[^{F28} [^{F29} 50)] mg]	[^{F29} (2)]pn- effervescent tablets and capsules		[^{F29} (2)]The quantity sold or supplied in one container or package

	Exemptions from the restrictions on the sale and supply of prescription only medicines			
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
				shall not exceed 32
		[^{F29} (3)]All preparations other than non- effervescent tablets or capsules		The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100]
Astemizole		F30	F30	F30
		F30 F30		
Atenolol				
Atracurium Besylate				
Atropine		(1) Internal		
		(a) by inhaler		
		(b) otherwise	(b) 300mcg (MD)	

			ictions on the sale and supp	ply of	
Column 1 Substance	prescription Column 2 Maximum strength	n only medicine Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
		than by inhaler			
			1mg (MDD)		
		(2) External (except ophthalmic)			
Atropine Methobromic	la	(1) Internal			
Wethooronno	le	(a) by inhaler			
		(b) otherwise than by inhaler	(b) 400mcg (MD)		
			1.3mg (MDD)		
		(2) External (except ophthalmic)			
Atropine		Internal			
Methonitrate		(a) by inhaler			
		(b) otherwise than by inhaler	(b) 400mcg (MD)		
			1.3mg (MDD)		
Atropine Oxide		(1) Internal			
Hydrochloric	le	(a) by inhaler			
		(b) otherwise than by inhaler	(b) 360mcg (MD)		
			1.2mg (MDD) 3		
		(2) External (except ophthalmic)			

	prescription	from the restruction only medicine	ictions on the sale and suppl	ly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Atropine Sulphoto		(1) Internal		
Sulphate		(a) by inhaler		
		(b) otherwise than by inhaler	(b) 360mcg (MD)	
			1.2mg (MDD)	
		(2) External (except ophthalmic)		
Auranofin				
Azapropazon	e			
Azathioprine				
Azathioprine Sodium				
Azelaic Acid				
Azelastine Hydrochlorid	e	For nasal administratio	140mcg per nostril (MD)	Container or package
		For the treatment of seasonal allergic rhinitis [^{F31} or perennial allergic rhinitis] For use in adults and	280mcg per nostril (MDD)	containing not more than 5,040mcg of Azelastine Hydrochloride
		children not less than [^{F32} 5 years]		
		As a non- aerosol,		

		Exemptions from the restrictions on the sale and supply of rescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity			
		aqueous form					
Azidocillin Potassium							
Azithromycin	l						
Azlocillin Sodium							
Aztreonam							
Bacampicillir Hydrochlorid							
Bacitracin							
Bacitracin Methylene Disalicylate							
Bacitracin Zinc							
Baclofen							
[^{F25} Balsalazid Sodium]	e						
Bambuterol Hydrochlorid	e						
Barium Carbonate							
Barium Chloride							
Barium Sulphide							
Beclamide							
Beclomethase	one						
Beclomethase Dipropionate	one	For nasal administratio (non- aerosol)	100mcg per nostril (MD)	Container or package containing not more than [^{F33} 20,000 mcg] of			

	-	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum	Column 3 Route of	Column 4 Treatment limitations	Column 5 Maximum		
	strength	administrati use or pharmaceut form		quantity		
		For the prevention	200 mcg per nostril (MDD)	Beclomethasone Dipropionate		
		and treatment of allergic rhinitis	[^{F34} For a maximum period of 3 months]			
		[^{F35} For use in persons aged 18 years and over]				
elladonna erb		(1) Internal	(1) 1mg of the alkaloids (MDD)			
		(2) External				
adonna t		(1) Internal	(1) 1mg of the alkaloids (MDD)			
		(2) External				
negride						
negride ium						
napryzine drochlorid	e					
drofluazi	de					
ethamine icillin						
ioxaprofei	1					
oeridol						
Benserazi	de]					
erazide cochlorid	e					
ntiromide						
nzathine nicillin						
nzbromaro	ne					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity		
Benzhexol Hydrochlorid	le					
Benzilonium Bromide						
Benzocaine		Any use except ophthalmic use				
Benzoctamin Hydrochlorid						
Benzoyl Peroxide	10.0 per cent	External				
N-Benzoyl Sulphanilami	de					
Benzquinami	de					
Benzquinami Hydrochlorid						
Benzthiazide						
Benztropine Mesylate						
Benzylpenici Calcium	llin					
Benzylpenici Potassium	llin					
Benzylpenici Sodium	llin					
Beractant						
Betahistine Hydrochlorid	le					
Betamethason	ne					
Betamethason Adamantoate						
Betamethason Benzoate	ne					

		from the restric only medicines	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Betamethaso Dipropionate				
Betamethaso Sodium Phosphate	ne			
Betamethaso Valerate	ne			
Betaxolol Hydrochloric	le			
Bethanechol Chloride				
Bethanidine Sulphate				
Bezafibrate				
[^{F22} Bicalutar	nide]			
Biperiden Hydrochlorid	le			
Biperiden Lactate				
Bismuth Glycollylarsa	nilate			
Bisoprolol Fumarate				
Bleomycin				
Bleomycin Sulphate				
Bretylium Tosylate				
[^{F25} Brimonid Tartrate]	ine			
Bromhexine Hydrochloric	le			
Bromocriptir Mesylate	ie			
Bromperidol				

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	, ,	Column 5 Maximum quantity	
Bromvaleton	e				
Brotizolam					
Budesonide		For nasal administratio	200mcg per nostril (MD) m	Container or package	
		For the prevention or treatment of seasonal allergic rhinitis	[^{F34} For a maximum period of 3 months]	containing not more than 10mg of Budesonide	
		200 mcg per nostril (MDD)			
		[^{F35} For use in persons aged 18 years and over]			
		As a non- aerosol, aqueous form			
Bufexamac					
Bumetanide					
Buphenine			6mg (MD)		
Hydrochlorid	le		18mg (MDD)		
Bupivacaine		Any use except ophthalmic use			
Bupivacaine Hydrochlorid	e	Any use except ophthalmic use			
Buserelin Acetate					

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Buspirone Hydrochloric	le			
Busulphan				
Butacaine Sulphate		Any use except ophthalmic use		
Butorphanol Tartrate				
Butriptyline Hydrochloric	le			
[^{F36} Cabergoli	ne]			
Calcipotriol				
[^{F22} Calcipotri Hydrate]	ol			
Calcitonin				
Calcitriol				
Calcium Amphomycii	1			
Calcium Benzamidosa	alicylate			
Calcium Bromide				
Calcium Bromidolacto	obionate			
Calcium Carbimide				
Calcium Folinate				
Calcium Metrizoate				
Calcium Sulphaloxate				
[^{F37} Candesart Cilexetil]	an			

	prescription	from the restri only medicine	ictions on the sale and suppose	vly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Candicidin				
Canrenoic Acid				
Cantharidin	0.01 per cent	External		
Capreomycii Sulphate	1			
Captopril				
Carbachol				
Carbamazep	ine			
Carbaryl				
[^{F25} Carbasala Calcium]	ite			
Carbenicillin Sodium	l			
Carbenoxolo	one	(1) Pellet	(1) 5mg (MD)	
Sodium			25mg (MDD)	
	(2) 2.0 per cent	(2) Gel		
	(3) 1.0 per cent	(3) Granules for mouthwash in adults and children not less than 12 years	(3) 20mg (MD) 80mg (MDD)	(3) Container or package containing not more than [^{F38} 560mg] of Carbenoxolone Sodium
Carbidopa				
Carbimazole				
Carbocistein				
Carbon Tetrachloride				
Carboplatin				

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Carboprost Trometamol						
Carbuterol Hydrochloride	9					
Carfecillin Sodium						
Carindacillin Sodium						
Carisoprodol						
Carmustine						
Carperidine						
Carteolol Hydrochloride	e					
Cefaclor						
Cefadroxil						
Cefazedone Sodium						
[^{F25} Cefdinir]						
Cefixime						
Cefodizime Sodium						
Cefotaxime Sodium						
Cefoxitin Sodium						
Cefpodoxime Proxetil						
[^{F36} Cefprozil]						
Cefsulodin Sodium						
Ceftazidime						
Ceftizoxime Sodium						

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity		
Ceftriaxone Sodium						
Cefuroxime Axetil						
Cefuroxime Sodium						
Celiprolol Hydrochlorid	e					
Cephalexin						
Cephalexin Sodium						
Cephaloridine	e					
Cephalothin Sodium						
Cephamandol Nafate	e					
Cephazolin Sodium						
Cephradine						
Cerium Oxalate						
Cerivastatin						
[^{F25} Cerivastati Sodium]	in					
Ceruletide Diethylamine						
Cetirizine Hydrochlorid	e		10mg (MDD)	F39		
Chenodeoxyc Acid	holic					
Chloral Hydrate		External				
Chlorambucil						
Chloramphen	icol					

		from the restri	ictions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Chloramphen Cinnamate	nicol			
Chloramphen Palmitate	nicol			
Chloramphen Sodium Succinate	nicol			
Chlorhexadol	l			
Chlormadino Acetate	ne			
Chlormerodri	in			
Chlormethiaz	zole			
Chlormethiaz Edisylate	zole			
Chlormezano	one			
Chloroform(3	3 (1) 5.0 per cent	(1) Internal		
		(2) External		
Chloroquine Phosphate		Prophylaxis of malaria		
Chloroquine Sulphate		Prophylaxis of malaria		
Chlorothiazic	le			
Chlorotrianis	ene			
Chlorphenox: Hydrochlorid	amine le			
Chlorpromaz	ine			
Chlorpromaz Embonate	ine			
Chlorpromaz Hydrochlorid				
Chlorpropam	ide			

⁽³⁾ SeeS.I. 1979/382 amended by S.I. 1980/263 and S.I. 1989/1124.

Column 1 Column 2 Column 3 Column 4 Column 4 Substance Maximum strength Route of Treatment limitations Maximu quantity administration, use or pharmaceutical form Treatment limitations Maximu quantity Chlorprothixene Chlorprothixene Chlortetracycline Chlortetracycline Chlortetracycline Chlortetracycline	m
Chlorprothixene Hydrochloride Chlortetracycline Chlortetracycline Calcium Chlortetracycline	
Hydrochloride Chlortetracycline Calcium Chlortetracycline	
Chlortetracycline Calcium Chlortetracycline	
Calcium Chlortetracycline	
Hydrochloride	
Chlorthalidone	
Chlorzoxazone	
Cholestyramine	
Ciclacillin	
Ciclobendazole	
Cilastatin Sodium	
Cilazapril	
Cimetidine (a) For the (a) 200mg (MD)	
short-term symptomatic 800mg (MDD)	
relief of For a maximum period of heartburn, 14 days dyspepsia, indigestion, acid indigestion and hyperacidity and for the prophylaxis of meal- induced	
heartburn (b) For the (b) 100 mp (MD) to be	
(b) For the (b) 100mg (MD) to be prophylactic taken as a single dose at management night	
of nocturnal heartburn by a single For a maximum period of 14 days	

		from the restri only medicine	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		dose taken at night		
Cimetidine Hydrochlorid	de			
Cinchocaine	3.0 per cent	Non- ophthalmic use		
Cinchocaine Hydrochlorid		Non- ophthalmic use		
Cinchophen				
Cinoxacin				
Ciprofibrate				
Ciprofloxaci	n			
Ciprofloxaci Hydrochlorid				
Cisapride				
Cisplatin				
[^{F22} Citalopra Hydrobromi				
Clarithromy	cin			
Clavulanic Acid				
Clidinium Bromide				
Clindamycin	l			
Clindamycin Hydrochlorid				
Clindamycin Palmitate Hydrochlorid				
Clindamycin Phosphate	L			

		from the restring only medicine	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
Clioquinol		(1) External (other than treatment of mouth ulcers)		
	(2) 35mg	(2) Treatment of mouth ulcers	(2) 350mg (MDD)	
Clobetasol Propionate				
Clobetasone Butyrate	[^{F40} 0.05 per cent]	[^{F40} Cream for use in adults and in children aged 12 years and over, for external use for the short term symptomatic treatment and control of patches of eczema and dermatitis (excluding seborrhoeic dermatitis)]		[^{F40} Container or package containing not more than 15g of medicinal product]
Clofazimine				
Clofibrate				
Clomiphene Citrate				
Clomipramin				
Clomipramin Hydrochlorid	e			
Clomocycline	e			

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Clomocycline Sodium	5					
Clonidine						
Clonidine Hydrochlorid	e					
Clopamide						
Clopenthixol Decanoate						
Clopenthixol Hydrochlorid	e					
Clorexolone						
Clotrimazole		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis				
Cloxacillin Benzathine						
Cloxacillin Sodium						
Clozapine						
Cocculus Indicus						
Co- dergocrine Mesylate						
Colaspase						
Colchicine						
Colestipol Hydrochlorid	e					
Colfosceril Palmitate						

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceute form		Column 5 Maximum quantity	
Colistin Sulphate					
Colistin Sulphometha	te				
Colistin Sulphometha Sodium	te				
Coniine					
Conium Leaf	7.0 per cent	External			
Corticotrophi	n				
Cortisone					
Cortisone Acetate					
Co- tetroxazine					
Co- trimoxazole					
Cropropamid	e				
Crotethamide	•				
Croton Oil					
Croton Seed					
Curare					
Cyclofenil					
Cyclopenthia	zide				
Cyclopentola Hydrochlorid					
Cyclophosph	amide				
Cycloserine					
Cyclosporin					
Cyclothiazide	2				
Cyproterone Acetate					

		from the restric only medicines	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Cytarabine				
Cytarabine Hydrochlorid	e			
Dacarbazine				
Dalteparin Sodium				
Danazol				
Danthron				
Dantrolene Sodium				
Dapsone				
Dapsone Ethane Ortho Sulphonate				
Daunorubicin Hydrochlorid				
Deanol Bitartrate			26mg (MDD)	
Debrisoquine Sulphate				
Demecarium Bromide				
Demeclocycli	ne			
Demeclocycli Calcium	ne			
Demeclocycli Hydrochlorid				
Deoxycortone Acetate	2			
Deoxycortone Pivalate	2			
Deptropine Citrate				

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 C	Column 4 Freatment limitations	Column 5 Maximum quantity		
Dequalinium Chloride	n (1) 0.25mg	(1) Internal: throat lozenges or throat pastilles				
	(2) 1.0 per cent	(2) External: paint				
Deserpidine						
Desferrioxan Mesylate	nine					
Desflurane						
Desipramine Hydrochlorid						
Deslanoside						
Desmopressi	n					
Desmopressi Acetate						
Desogestrel						
Desonide						
Desoxymeth	asone					
Dexamethas						
Dexamethase Acetate	one					
Dexamethase Isonicotinate						
Dexamethase Phenylpropie						
Dexamethase Pivalate	one					
Dexamethase Sodium Metasulphob						
Dexamethase Sodium Phosphate						

		from the restri only medicine	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
Dexamethas Troxundate	one			
Dexfenflurar Hydrochlorid				
Dextromethorphan Hydrobromide		Internal	(a) In the caseof a prolongedrelease preparation:equivalent of 30mg ofDextromethorphan (MD)	
			equivalent of 75mg of Dextromethorphan (MDD)	
			(b) in any other case: equivalent of 15mg of Dextromethorphan (MD)	
			equivalent of 75mg of Dextromethorphan (MDD)	
Dextrothyroz Sodium	kine			
Diazoxide				
Dibenzepin Hydrochlorid	le			
Dichloralphe	enazone			
Dichlorphen	amide			
Diclofenac	1.16 per	External	For maximum period of 7	Container
Diethylamm	oithann	For local symptomatic relief of pain and inflammation in trauma of the tendons, ligaments, muscles and joints and in localised forms of	days	or package containing not more than 30g of medicinal product

		from the restrient only medicine	ctions on the sale and sup s	ply of
Column 1 Substance	Column 2 Maximum trength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		soft tissue rheumatism		
		For use in adults and children not less than 12 years		
Diclofenac Potassium				
Diclofenac Sodium				
Dicyclomine			10mg (MD)	
Hydrochloride			60mg (MDD)	
[^{F21} Didanosine]				
Dienoestrol				
Diethanolamine Fusidate	2			
Diflucortolone Valerate				
Diflunisal				
Digitalin				
Digitalis Leaf				
Digitalis Prepared				
Digitoxin				
Digoxin				
Dihydralazine Sulphate				
Dihydroergotan Mesylate	nine			
Dihydrostreptor	mycin			
Dihydrostreptor Sulphate	mycin			

		from the restric only medicines	tions on the sale and su	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form	, ,	Column 5 Maximum quantity
Diloxanide Furoate				
Diltiazem Hydrochloric	le			
Dimercaprol				
Dimethisoqu Hydrochloric		Non- ophthalmic use		
Dimethistero	one			
Dimethothia: Mesylate	zine			
Dimethyl Sulphoxide				
Dimethyltub Bromide	ocurarine			
Dimethyltub Chloride	ocurarine			
Dimethyltub Iodide	ocurarine			
Dinoprost				
Dinoprost Trometamol				
Dinoprostone	e			
[^{F24} Diphenhy Hydrochloric	dfainine depreparations except liquid-filled capsules]			
[^{F41} Diphenox Hydrochlorid		[^{F41} In combination with Atropine Sulphate for short term use as an adjunctive therapy to	[^{F41} 25 mg (MDD)]	[^{F41} Container or package containing not more than 20 tablets]

	prescription	from the restri		y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceute		Column 5 Maximum quantity
		<i>form</i> appropriate rehydration in acute diarrhoea For use in		
		persons aged 16 years and over		
		Tablets]		
Dipivefrin Hydrochloride	e			
Dipyridamole	;			
Disodium Etidronate				
Disodium Pamidronate				
Disopyramide	e			
Disopyramide Phosphate	2			
Distigmine Bromide				
Disulfiram				
Dithranol	1.0 per cent			
Dobutamine Hydrochloride	e			
[^{F41} Dolasetron Mesilate]	1			
Domperidone		[^{F42} For the relief of post- prandial symptoms of excessive fullness, nausea, epigastric	[^{F42} 10mg of Domperidone (MD)] [^{F42} 40mg of Domperidone (MDD)]	[^{F42} Container or package containing not more than 200mg of Domperidone]

		from the restri 1 only medicine	ctions on the sale and supply	v of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum	Route of	Treatment limitations	Maximum
	strength	administrati	on,	quantity
		use or pharmaceuti	ical	
		form		
		bloating and		
		belching,		
		occasionally		
		accompanied by		
		epigastric		
		discomfort		
		and		
		heartburn]		
Domperidone	e	[^{F43} For	[^{F44} 10 mg of Domperidone	-
Maleate		the relief	as Domperidone Maleate	or package
		of post- prandial	(MD)]	containing not more
		symptoms	[^{F44} 40 mg of Domperidone	than
		of excessive	as Domperidone Maleate	[^{F45} 200mg]
		fullness,	(MDD)]	of
		nausea,		Domperidone
		epigastric bloating and		as Domnoridono
		belching,		Domperidone Maleate;]
		occasionally		
		accompanied		
		by epigastric		
		discomfort		
		and		
		heartburn,]		
[^{F25} Donepezil Hydrochlorid	e]			
Dopamine Hydrochlorid	e			
Dopexamine				
Hydrochlorid	e			
[^{F22} Dorzolam	ide			
Hydrochlorid				
Dothiepin				
Dothiepin Hydrochlorid	e			
Doxapram Hydrochlorid	e			
	-		17	
			47	

	prescription	from the restruction only medicine	ictions on the sale and suppose	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Doxazosin Mesylate					
Doxepin Hydrochlorid	e				
Doxorubicin					
Doxorubicin Hydrochlorid	e				
Doxycycline					
Doxycycline Calcium Chelate					
Doxycycline Hydrochlorid	e				
Droperidol					
Dydrogestero	one				
Dyflos					
Econazole		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis			
Econazole Nitrate		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis			
Ecothiopate Iodide					
Edrophonium Chloride	1				

Exemptions from the restrictions on the sale and supply of prescription only medicines				oly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Eflornithine Hydrochloric	le			
[^{F21} Eformote: Fumarate]	rol			
Embutramide	9			
Emepronium Bromide				
Emetine	1.0 per cent			
Emetine Bismuth Iodide				
Emetine Hydrochloric	Equivalent loof 1.0 per cent of Emetine			
Enalapril Maleate				
Encephalitis Virus, Tick- borne, Cent Eur				
Enoxacin				
Enoxaparin Sodium				
Enoximone				
Ephedrine		(1) Internal (other than nasal sprays or nasal drops)	(1) 30mg (MD)	
			60mg (MDD)	
	(2) 2.0 per cent	(2) Nasal sprays or nasal drops(3) External		

		from the restri only medicine	ictions on the sale and supply	v of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Ephedrine Hydrochlorid	le	(1) Internal (other than	(1) Equivalent of 30mg of Ephedrine (MD)	
		nasal sprays or nasal drops)	Equivalent of 60mg of Ephedrine (MDD)	
	(2) Equivalent of 2.0 per cent of Ephedrine	(2) Nasal sprays or nasal drops		
		(3) External		
Ephedrine Sulphate		(1) Internal (other than nasal sprays or nasal drops)	(1) Equivalent of 30mg of Ephedrine (MD)	
			Equivalent of 60mg of Ephedrine (MDD)	
	(2) Equivalent of 2.0 per cent of Ephedrine	(2) Nasal sprays or nasal drops		
		(3) External		
Epicillin				
Epirubicin				
Epirubicin Hydrochlorid	le			
Epithiazide				
Epoetin Alfa				
Epoetin Beta				
Epoprosteno Sodium	l			
Ergometrine Maleate				

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity		
Ergometrine Tartrate						
Ergot, Prepared						
Ergotamine Tartrate						
Erythromycir	1					
Erythromycir Estolate	1					
Erythromycir Ethylcarbona						
Erythromycir Ethyl Succinate	1					
Erythromycir Lactobionate	1					
Erythromycir Phosphate	1					
Erythromycir Stearate	1					
Erythromycir Thiocyanate	1					
Esmolol Hydrochlorid	e					
Estramustine Phosphate						
[^{F46} Estramust Sodium Phosphate]	ine					
Etafedrine Hydrochlorid	e					
Ethacrynic Acid						
Ethambutol Hydrochlorid	e					

		Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Ethamivan						
Ethamsylate						
Ethiazide						
Ethinyl Androstened	iol					
Ethinyloestra	diol					
Ethionamide						
Ethisterone						
Ethoglucid						
Ethoheptazin Citrate	e					
Ethopropazir Hydrochloric						
Ethosuximid	e					
Ethotoin						
Ethyl Biscoumacet	ate					
Ethynodiol Diacetate						
Etodolac						
Etomidate						
Etomidate Hydrochloric	le					
Etoposide						
Etretinate						
[^{F22} Exemesta	ne]					
Famciclovir						
Famotidine		For the	10mg (MD)			
		short-term symptomatic	20mg (MDD)			
		relief of heartburn, dyspepsia,	For maximum period of 14 days			
		indigestion,	52			

		from the restri n only medicine	ctions on the sale and suppl	ly of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum	Route of	Treatment limitations	Maximum
	strength	administrati	on,	quantity
	C	use or		1
		pharmaceuti	ical	
		form		
		acid		
		indigestion		
		and		
		hyperacidity,		
		and		
		prevention		
		of these		
		symptoms		
		when associated		
		with food		
		and drink,		
		including		
		nocturnal		
		symptoms		
Fazadinium				
Bromide				
Felbinac	3.17 per	External	For maximum period of 7	Container
	cent	^{F48} For the	days	or package
		relief of		containing
		rheumatic		not more
		pain, pain of		than
		non-serious		[^{F47} 50g] of
		arthritic		medicinal
		conditions		product
		and soft		
		tissue		
		injuries such		
		as sprains,		
		strains and		
		contusions]		
		For use in		
		adults and		
		children not		
		less than 12		
		years		
Felodipine		years		
Felodipine Felypressin		years		
-		years		
Felypressin		years		

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity		
Fenfluramine Hydrochlorie						
Fenofibrate						
Fenoprofen						
Fenoprofen Calcium						
Fenoterol Hydrobromi	de					
Fenticonazol Nitrate	e	[^{F40} External use (but in the case of vaginal use, only for the treatment of vaginal candidiasis)]				
Feprazone						
Ferrous Arsenate						
[^{F22} Ferumoxs	sil]					
[^{F25} Fexofena Hydrochlorid						
Filgrastim						
Finasteride						
Flavoxate Hydrochlorid	le					
Flecainide Acetate						
Flosequinan						
Fluanisone						
Flubendazol	e					
Fluclorolone Acetonide						
Flucloxacilli Magnesium	n					

	prescription	from the restr 1 only medicin	ictions on the sale and suppersisted and suppersis	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrat use or pharmaceut form		Column 5 Maximum quantity
Flucloxacilli Sodium	n			
Fluconazole		For oral administration for the treatment of vaginal candidiasis [^{F49} or associated candidal balanitis] in persons aged not less than 16 but less than 60 years		Container or package containing not more than 150mg of Fluconazole
Flucytosine				
Fludrocortise Acetate	one			
Flufenamic Acid				
Flumazenil				
Flumethason	ne			
Flumethason Pivalate	ie			
Flunisolide	0.025 per cent	(a) For the prevention and treatment of seasonal allergic rhinitis, including hay fever	(a) 50mcg per nostril(MD)100mcg per nostril(MDD)	(a) Container or package containing not more than 6,000mcg of Flunisolide
		[^{F50} For use in persons aged 18	[^{F51} For a maximum period of 3 months]	

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form years and		Column 5 Maximum quantity		
		over]				
		In the form of a non- pressurised nasal spray				
		F52	F52	F52		
			F52			
		F52				
		F52				
Fluocinolone Acetonide						
Fluocinonide						
Fluocortin Butyl						
Fluocortolone	e					
Fluocortolone Hexanoate	2					
Fluocortolone Pivalate	2					
Fluorescein Dilaurate						
Fluoromethol	one					
Fluorouracil						
Fluorouracil Trometamol						
Fluoxetine Hydrochlorid	e					
Flupenthixol Decanoate						

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity		
Flupenthixol Hydrochlorid	e					
Fluperolone Acetate						
Fluphenazine Decanoate						
Fluphenazine Enanthate						
Fluphenazine Hydrochlorid						
Flupredniden Acetate	e					
Fluprednisolo	one					
Fluprostenol Sodium						
Flurandrenolo	one					
Flurbiprofen	[^{F53} 8.75 mg]	[^{F54} Throat lozenges]	[^{F55} 43.75 mg (MDD)]	[^{F56} Container or package containing not more than 140 mg of Flurbiprofen]		
Flurbiprofen Sodium						
Fluspirilene						
Flutamide						
Fluticasone Propionate						
[^{F25} Flutrimazo	ole]					
Fluvastatin Sodium						
Fluvoxamine Maleate						
Folic Acic			500mcg (MDD)			

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity	
Formestane					
Formocortal					
Foscarnet Sodium					
Fosfestrol Sodium					
Fosfomycin Trometamol					
Fosinopril Sodium					
Framycetin Sulphate					
Frusemide					
Furazolidone					
Fusafungine					
Fusidic Acid					
Gabapentin					
Gadoteridol					
Gallamine Triethiodide					
Ganciclovir					
Ganciclovir Sodium					
Gelsemine	0.1 per cent				
Gelsemium			25mg (MD)		
			75mg (MDD)		
Gemeprost					
Gemfibrozil					
Gentamicin					
Gentamicin Sulphate					
Gestodene					

		from the restric only medicine.	ctions on the sale and sup s	oply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity	
Gestrinone					
Gestronol					
Gestronol Hexanoate					
Glibenclamide	e				
Glibornuride					
Gliclazide					
Glipizide					
Gliquidone					
Glisoxepide					
Glucagon					
Glycopyrroniu Bromide	um		1mg (MD) 2mg (MDD)		
Glymidine					
Gonadorelin					
Goserelin Acetate					
Gramicidin	0.2 per cent	External			
Granisetron Hydrochloride	e				
Griseofulvin					
Growth Hormone					
Guanethidine Monosulphate	e				
Guanfacine Hydrochloride	9				
Guanoclor Sulphate					
Guanoxan Sulphate					

		from the restruction only medicine	ictions on the sale and suppers	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Halofantrine Hydrochlori				
Haloperidol				
Haloperidol Decanoate				
Heparin		External		
Heparin Calcium		External		
Heparin Sodium				
Hexachlorop	hane	External		
	(a) 2.0 per cent	(a) Soaps		
	(b) 0.1 per cent	(b) Aerosols		
	(c) 0.75 per cent	(c) preparations other than soaps and aerosols		
Hexamine Phenylcinch	oninate			
Hexobarbito	ne			
Hexobarbito Sodium	ne			
Hexoestrol				
Hexoestrol Dipropionate	2			
L-Histidine Hydrochlori	de	Dietary supplementa	tion	
Homatropine	e	(1) Internal	(1) 0.15mg (MD)	
			0.45mg (MDD)	
		(2) External (except ophthalmic)		

		from the restri only medicine	ctions on the sale and sup	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Homatropine			0.2mg (MD)	
Hydrobromid	e		0.6mg (MDD)	
Homatropine			2mg (MD)	
Methylbromic	de		6mg (MDD)	
Hydralazine Hydrochlorid	e			
Hydrargapher	1	Local application to skin		
Hydrobromic Acid				
Hydrochlorot	hiazide			
Hydrocortiso	ne [^{F57} (1) 0.5 per cent]	 [^{F57}(1) Ex (a) For use in combin with Nystati of maximus strength 3.0 per cent for intertris (b) For use in adults and children not less than 10 years] 	ation n um 1 go	(Containing or package containing not more than 15g of medicinal product]
	[^{F58} (2)]1.0 per cent	[^{F58} (2)] Ez (a) For use either alone	kternal	(ජීතී(22))Iner or package containing not more than 15g

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration,	Column 5 Maximum quantity			
		use or				
		pharmaceutical form				
		or in	of medicinal			
		conjunction	product			
		with	(cream or			
		Crotamiton	ointment) or			
		in	30ml (spray)			
		irritant				
		dermatitis,				
		contact allergic				
		dermatitis,				
		insect				
		bite				
		reactions,				
		mild				
		to				
		moderate				
		eczema, and				
		either				
		in				
		combination				
		with				
		Clotrimazole				
		[^{F59} 01				
		Miconazole				
		Nitrate]				
		for othlata's				
		athlete's foot				
		and				
		candidal				
		intertrigo				
		or in				
		combination				
		with				
		lignocaine				
		for anal				
		and				
		perianal				
		itch				
		associated				
		with				
		haemorrhoids				

		from the restri only medicine	ctions on the sale and sup	oply of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum	Route of	Treatment limitations	Maximum
Substance	strength	administrati		quantity
	sirengin	use or	011,	quantity
		pharmaceuti	ical	
		form	cui	
		U		
		(b) For		
		use in adults		
		and childrer	-	
			1	
		not		
		less		
		than		
		10		
		years		
		(c) Cream	at	
		ointmer	11	
		or		
		spray		
	onEquivalent	External		
Acetate	to 1.0	For use		Container
	per cent			or package
	Hydrocortiso	ne dermatitis		containing
		contact		not more
		allergic		than 15g of
		dermatitis,		medicinal
		insect bite		product
		reactions,		
		mild to		In the
		moderate		case of
		eczema,		suppositories,
		and in		container
		combination		or package
		with one or		containing
		more of the		no more
		following:		than 12
		Benzyl		
		Benzoate,		
		Bismuth		
		Oxide,		
		Bismuth		
		Subgallate,		
		Peru		
		Balsam,		
		Pramoxine		
		Hydrochlorid	le.	
		Zinc	,	
		Oxide, for		
		haemorrhoids	5	
			63	

		<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio	Column 4 Treatment limitations on,	Column 5 Maximum quantity			
		<i>form</i> [^{F60} or in combination with Miconazole Nitrate, for athlete's foot and candidal intertrigo]					
		For use in adults and children not less than 10 years					
		Cream, ointment or suppositories					
Hydrocortisc Butyrate	one						
Hydrocortisc Caprylate	one						
Hydrocortisc Hydrogen Succinate	one						
Hydrocortisc Sodium Phosphate	one						
Hydrocortisc Sodium Succinate	onEquivalent to 2.5mg Hydrocortisc	External For aphthous ulceration of the mouth for adults and children not less than 12 years In the form of pellets		Container or package containing not more than equivalent to 50mg of Hydrocortisone			

	prescription	from the restrient from the restrient from the restrict from the second se	ctions on the sale and sup s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
[^{F24} Hydrocya Acid]	nic			
Hydroflumet	hiazide			
Hydroxychlo Sulphate	oroquine	Prophylaxis of malaria		
Hydroxyprog	gesterone			
Hydroxyprog Enanthate	gesterone			
Hydroxyprog Hexanoate	gesterone			
Hydroxyurea	L			
Hydroxyzine Embonate				
Hydroxyzine Hydrochlorid		(a) For the management of pruritis associated with acute or chronic urticaria or atopic dermatitis or contact dermatitis, in adults and in children not less than 12 years	(a) 25mg (MD) 75mg (MDD)	(a) Container or package containing not more than 750mg of Hydroxyzine Hydrochloride
		(b) For the management of pruritis associated with acute or chronic urticaria or atopic dermatitis or contact dermatitis,	(b) 25 mg (MD) 50mg (MDD)	 (b) Container or package containing not more than 750mg of Hydroxyzine Hydrochloride

		from the restri only medicine	ctions on the sale and sup s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati- use or pharmaceuth form in children not less than		Column 5 Maximum quantity
		6 years but less than 12 years		
Hyoscine	(1) 0.15 per cent	(1) Internal		
		(2) External (except ophthalmic)		
Hyoscine		(1) Internal		
Butylbromide		(a) by inhaler		
		(b) otherwise than by inhaler	(b) 20mg (MD) 80mg (MDD)	(b) Container or package containing not more than 240mg of Hyoscine Butylbromide
		(2) External		
Hyoscine		(1) Internal		
Hydrobromic	le	(a) by inhaler		
		(b)	(b) 300mcg (MD)	
		otherwise than by inhaler	900mcg (MDD)	
		(2) External (except ophthalmic)		
Hyoscine		(1) Internal		
	te	(a) by		
Methobromic		inhaler		
Methobromic		(b) otherwise	(b) 2.5mg (MD)	

Column 1 Column 2 Column 3 Column 4 Column 5 Substance Maximum strength Route of administration, use or pharmaceutical form Maximum quantity Hyoscine than by inhaler (2) External Hyoscine (1) Internal (a) by inhaler (b) (b) 2.5mg (MD) (2) External 7.5mg (MDD) (2) External (b) (b) 2.5mg (MD) (1) Internal (a) by inhaler (2) External (b) (b) 2.5mg (MD) (1) Internal (a) by inhaler (2) External (D) (Dherwise than by inhaler (2) External (b) (b) 300mcg (MD) (b) (b) collerwise than by inhaler (b) (b) 300mcg (MD) (1) Internal (a) by inhaler (2) External (b) (b) Source (MD) Hyoscyamine (1) Internal Hyoscyamine (2) External Hyoscyamine (2) External Hyoscyamine (2) External Hyoscyamine (1) Internal (a) by inhaler (b) (b) Equivalent of 300mcg of Hyoscyamine (MDD) (b) inhaler (b) Equivalent of 300mcg of Hyoscyamine (MDD)			from the restruction only medicine	ictions on the sale and supply	y of
42) ExternalHyoscine Methonitrate(1) Internal (a) by inhaler(b) otherwise than by inhaler(b) 2.5mg (MD) 7.5mg (MDD)(1) Internal (2) ExternalHyoscyamine(1) Internal (a) by inhaler(2) ExternalHyoscyamine(1) Internal (a) by inhaler(2) ExternalHyoscyamine(b) 3000mcg (MD) otherwise than by inhalerHyoscyamine(1) Internal (2) ExternalHyoscyamine(1) Internal (a) by inhalerHyoscyamine(1) Internal (a) by inhalerHyoscyamine(1) Internal (a) by inhalerHyoscyamine(b) Equivalent of 300mcg of Hyoscyamine (MD) than by inhalerHyoscyamine(1) Internal (A) by inhalerHyoscyamine(b) Equivalent of 300mcg of Hyoscyamine (MD) than by inhalerHyoscyamine(b) by (b) Equivalent of 1mg of Hyoscyamine (MD)Hyoscyamine(b) Equivalent of 300mcg of Hyoscyamine (MD)Hyoscyamine(b) Equivalent of 300mcg of Hyoscyamine (MD)Hyoscyamine(b) Equivalent of 1mg of of Hyoscyamine (MD)Hyoscyamine(b) Equivalent of 300mcg of Hyoscyamine (MD)Hyoscyamine(b) Equivalent of 1mg of of Hyoscyamine (MD)		Maximum	Route of administrati use or pharmaceut form than by	Treatment limitations on,	Maximum
Hyoscine Methonitrate (1) Internal (a) by inhaler (b) otherwise than by inhaler (2) External (1) Internal (a) by inhaler (2) External (b) otherwise than by inhaler (2) External (b) (b) 300mcg (MD) (1) (mg (MDD) (1) (MDD) (1) (1) (2) External (1) Internal (2) External (1) Internal (2) External (1) Internal (3) by inhaler (1) Internal (2) External (3) by inhaler (1) Internal (4) by inhaler (1) Internal (5) (5) (5) Equivalent of 300mcg (5) (5) Equivalent of 1mg of Hyoscyamine (MDD) (2) External (4) by inhaler (5) (5) Equivalent of 300mcg (5) Equivalent of 300mcg (5) Equivalent of 300mcg (5) Equivalent of 1mg of Hyoscyamine (MDD) (5) Equivalent of 300mcg (5) Equivalent of 300mcg (5) Equivalent of 300mcg (5) Equivalent of 1mg of (5) Equivalent of 300mcg (5) Equivalent of 1mg of (5) Equivalent of 300mcg (5) E					
Methonitrate(a) by inhaler(b) otherwise than by inhaler(b) 2.5mg (MD) 7.5mg (MDD)(b) otherwise than by inhaler(b) 2.5mg (MDD) 7.5mg (MDD)(1)Internal (a) by inhaler(b) otherwise than by inhaler(b) 300mcg (MD) 1mg (MDD)(1)Internal (a) by inhaler(2)External(b) otherwise than by inhaler(b) 300mcg (MD) 1mg (MDD)(1)Internal 	Hyoscine				
otherwise than by inhaler7.5mg (MDD)Hyoscyamine(1) Internal (a) by inhaler(b) (b) 300mcg (MD) (b) 300mcg (MD) (mmuleich and by inhalerHyoscyamine Hydrobromide(1) Internal (a) by inhaler(b) (c) ExternalHyoscyamine Hydrobromide(1) Internal (a) by inhaler(b) (b) (c) ExternalHyoscyamine Hydrobromide(1) Internal (a) by inhaler(b) Equivalent of 300mcg of Hyoscyamine (MD) (MDD)Hyoscyamine Sulphate(1) Internal (a) by inhaler(b) C (c) ExternalHyoscyamine Sulphate(1) Internal (a) by inhaler(b) C (c) ExternalHyoscyamine Sulphate(1) Internal (a) by inhaler(b) C (c) ExternalHyoscyamine Sulphate(b) (c) Equivalent of 300mcg of Hyoscyamine (MDD)Equivalent of Img of Hyoscyamine (MD)(b) C (c) Equivalent of 300mcg of Hyoscyamine (MD)Hyoscyamine (mhaler(b) C (c) Equivalent of 300mcg of Hyoscyamine (MD)Hyoscyamine (mhaler(b) C (c) Equivalent of 300mcg of Hyoscyamine (MD)Hyoscyamine (mhaler(b) C (c) Equivalent of 100 of Equivalent of 100 of			(a) by		
Hyoscyamine(1) Internal(a) by inhaler(b) otherwise than by inhaler(b) 300mcg (MD) Img (MDD)(b) otherwise than by inhaler(b) 300mcg (MD) Img (MDD)Hyoscyamine (1) Internal (a) by inhaler(b) Equivalent of 300mcg of Hyoscyamine (MD) Equivalent of 1mg of Hyoscyamine (MDD)Hyoscyamine Sulphate(1) Internal (a) by inhalerHyoscyamine (b) otherwise than by inhaler(b) Equivalent of 300mcg of Hyoscyamine (MDD) Equivalent of 1mg of Hyoscyamine (MDD)Hyoscyamine (a) by inhaler(b) Equivalent of 300mcg of Hyoscyamine (MDD) Equivalent of 1mg of Hyoscyamine (MDD)Hyoscyamine (b) otherwise than by inhaler(b) Equivalent of 300mcg of Hyoscyamine (MD) Equivalent of 1mg of inhaler			otherwise than by		
(a) by inhaler(b) otherwise than by 			(2) External		
inhaler(b) otherwise than by inhaler(b) 300mcg (MD) Img (MDD)1mg (MDD)1mg (MDD)(2) External(2) External(1) Internal (a) by inhaler(b) otherwise than by inhaler(b) otherwise than by inhaler(b) (2) External(2) External(3) by inhaler(1) Internal (2) External(2) External(1) Internal (2) External(1) Internal (a) by inhaler(1) Internal (a) by inhaler(b) (b) (c) External(b) (c) b) (c) External(b) (c) b) (c) b) (c) b) contervise (c) b) (c) b) contervise (c) b) (c) b) contervise (c) b) (c) b) contervise (c) c) c) c) contervise (c) c) c) c) contervise (c) c) c) contervise (Hyoscyamine	e	(1) Internal		
otherwise than by inhalerImg (MDD)Hyoscyamine Hydrobromide(1) Internal (a) by inhaler(b) (b) (b) Equivalent of 300mcg of Hyoscyamine (MD) Equivalent of 1mg of Hyoscyamine (MDD)Hyoscyamine Sulphate(1) Internal (a) by inhaler(b) Equivalent of 1mg of Hyoscyamine (MDD)Hyoscyamine Sulphate(1) Internal (a) by inhaler(b) Equivalent of 300mcg of Hyoscyamine (MDD)(b) (c) External (b) inhaler(b) Equivalent of 300mcg of Hyoscyamine (MDD)(b) otherwise inhaler(b) Equivalent of 300mcg of Hyoscyamine (MD)(b) inhaler(b) Equivalent of 300mcg of Hyoscyamine (MD)(b) inhaler(b) Equivalent of 1mg of inhaler			• •		
Hyoscyamine Hydrobromide(1) Internal (a) by inhaler(a) by inhaler(b) (b) Equivalent of 300mcg otherwise than by inhaler(b) (b) Equivalent of 1mg of Hyoscyamine (MDD)(2) External(1) Internal (a) by inhaler(a) by inhaler(b) (b) Equivalent of 300mcg of Hyoscyamine (MDD)(2) External(1) Internal (a) by inhaler(b) (b) Equivalent of 300mcg of Hyoscyamine (MD)(b) (b) Equivalent of 300mcg of Hyoscyamine (MD)(b) (b) Equivalent of 1mg of inhaler			otherwise than by		
Hydrobromide(a) by inhaler(b)(b) Equivalent of 300mcg otherwise(b)(b) Equivalent of 1mg of Hyoscyamine (MDD)(2) ExternalHyoscyamine(1) Internal 			(2) External		
(a) by inhaler(b)(b) Equivalent of 300mcg otherwise(b)(b) Equivalent of 1mg of Hyoscyamine (MDD)(2) ExternalHyoscyamine(1) Internal (a) by inhaler(b)(b) Equivalent of 300mcg otherwise(b)(b) Equivalent of 300mcg otherwise(b)(b) Equivalent of 300mcg otherwise(b)(b) Equivalent of 300mcg otherwise(b)(b) Equivalent of 1mg of Hyoscyamine (MD)(c)(c) Equivalent of 1mg of (c) Equivalent of 1mg of			(1) Internal		
otherwise than by inhalerof Hyoscyamine (MD)Equivalent of 1mg of Hyoscyamine (MDD)(2) External(1) Internal Sulphate(a) by inhaler(b) otherwise than by inhaler(b) otherwise than by inhaler(b) otherwise than by inhaler(b) otherwise than by inhaler(b) than by inhaler(b) than by inhaler(c) than by than by than by than by than by than by than by than by th	Hydrobromic	le	• •		
Hyoscyamine (1) Internal Sulphate (a) by inhaler (b) (b) (b) Equivalent of 300mcg otherwise of Hyoscyamine (MD) than by Equivalent of 1mg of			otherwise than by	of Hyoscyamine (MD) Equivalent of 1mg of	
Sulphate (a) by inhaler (b) (b) Equivalent of 300mcg otherwise of Hyoscyamine (MD) than by inhaler Equivalent of 1mg of			(2) External		
(a) by inhaler (b) (b) Equivalent of 300mcg otherwise of Hyoscyamine (MD) than by inhaler Equivalent of 1mg of		2	(1) Internal		
otherwise of Hyoscyamine (MD) than by inhaler Equivalent of 1mg of	Sulphate				
(2) External			otherwise than by inhaler	of Hyoscyamine (MD) Equivalent of 1mg of	

	-	from the restri	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Ibuprofen		Rheumatic and muscular pain, pain of non-serious arthritic conditions, backache, neuralgia, migraine, headache, dental pain, dysmenorrho feverishness, symptoms of colds and influenza		
		(1) Internal	(1)(a) In the case of a prolonged release preparation 600mg (MD)	
			1,200mg (MDD)	
			(b) in any other case 400mg (MD)	
			1,200mg (MDD)	
	(2) 5.0 per cent	(2) External		
	[^{F61} (3) 10.0 per cent]	[^{F61} (3) External]	[^{F61} (3) 125 mg (MD) 500 mg (MDD)]	[^{F61} (3) Container or package containing not more than [^{F62} 50g] of medicinal product]
[^{F24} Ibuprofen Lysine		Rheumatic and muscular pain, pain of non-serious arthritic	(a) in the case of a prolonged release preparation 600 mg (MD) 1,200 mg (MDD)	

68

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum	Column 3 Route of	Column 4 Treatment limitations	Column 5 Maximum	
	strength	administrati use or	ion,	quantity	
		pharmaceut	ical		
		form			
		conditions, backache,			
		neuralgia,			
		migraine,			
		headache,			
		dental pain, dysmenorrho)ea.		
		feverishness			
		symptoms			
		of colds and influenza			
		Internal	(b) in any other case		
		Interna	400 mg (MD) 1,200 mg (MDD)]		
Idarubicin Hydrochlorid	e				
Idoxuridine					
Ifosfamide					
Ignatius Bean					
[^{F21} Imidapril Hydrochloride	e]				
Imipenem Hydrochloride	e				
Imipramine					
Imipramine Hydrochloride	e				
Imipramine Ion					
Exchange Resin Bound Salt					
or Complex					
[^{F36} Indapamid	e]				
Indapamide Hemihydrate					
110mm y di di C					

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Indomethacin Sodium					
Indoprofen					
Indoramin Hydrochlorid	e				
Inosine Pranobex					
[^{F63} Insulin]					
Iodamide					
Iodamide Meglumine					
Iodamide Sodium					
Iohexol					
Iomeprol					
Iopamidol					
Iopentol					
Iothalamic Acid					
Ioversol					
Ioxaglic Acid					
Ipratropium Bromide					
Iprindole Hydrochlorid	e				
Iproniazid Phosphate					
[^{F25} Irbesartan]	l				
Isoaminile					
Isoaminile Citrate					
Isocarboxazid	l				

	prescription	n only medicine		
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
Isoconazole Nitrate		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis		
Isoetharine				
Isoetharine Hydrochloride	9			
Isoetharine Mesylate				
Isoniazid				
Isoprenaline Hydrochloride	9			
Isoprenaline Sulphate				
Isopropamide Iodide			Equivalent of 2.5mg of Isopropamide ion (MD)	
			Equivalent of 5.0mg of Isopropamide ion (MDD)	
Isotretinoin				
Isradipine				
Itraconazole				
Jaborandi		External		
Kanamycin Acid Sulphate				
Kanamycin Sulphate				
Ketamine Hydrochloride	e			

Column 1 Column 2 Substance Maximum strength	Column 3 Route of administratio use or pharmaceuti	Column 4 Treatment limitations	Column 5 Maximum
Ketoconazole 2.0 per cent	form		quantity
	[^{F64} (a)][^{F65} Ext For the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp In the form of a shampoo	reffa(4)] Maximum frequency of application of once every 3 days	[^{F64} (a)] Container or package containing not more than 120ml of medicinal product and containing not more than 2,400mg of Ketoconazole
	[^{F66} (b) For the treatment of the following mycotic infections of the skin: tinea pedis, tinea cruris and candidal intertrigo]		
Ketoprofen 2.5 per cent	External For rheumatic and muscular pain in adults and children not less than 12	For maximum period of 7 days	Container or package containing not more than 30g of medicinal product
Ketorolac Trometamol			
Ketotifen Fumarate			
Labetalol Hydrocholoride			

		from the restric only medicines	ctions on the sale and su	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations m,	Column 5 Maximum quantity
Lachesine Chloride				
Lacidipine				
Lamotrigine				
Lanatoside C				
Lanatoside Complex A, B and C				
[^{F36} Lansoprazo	le]			
Latamoxef Disodium				
[^{F36} Lercanidipi Hydrochloride				
Levallorphan Tartrate				
Levobunolol Hydrochloride				
		(1) Nasal sprays For the symptomatic treatment of seasonal allergic rhinitis		(1) Container or package containing not more than 10 ml of medicinal product
		(2) Aqueous eye drops		(2) Container
		For the symptomatic treatment of seasonal allergic conjunctivitis		or package containing not more than 4 ml of medicinal product]
[^{F67} Levocarniti	ne]	[^{F67} For dietary supplementati	on]	

		from the restring only medicine	ctions on the sale and supp	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Levodopa				
[^{F25} Levofloxad	cin]			
Levonorgestre	^{F68} 0.75mg	[^{F68} for use as an emergency contraceptive in women aged 16 years and over]		
Lidoflazine				
Lignocaine		Non- ophthalmic use		
Lignocaine Hydrochloride	2	Non- ophthalmic use		
Lincomycin				
Lincomycin Hydrochloride	e			
Liothyronine Sodium				
Lisinopril				
Lithium Carbonate			Equivalent of 5mg of Lithium (MD)	
			Equivalent of 15mg of Lithium (MDD)	
Lithium Citrate				
Lithium Succinate				
Lithium Sulphate			Equivalent of 5mg of Lithium (MD)	
			Equivalent of 15mg of Lithium (MDD)	
Lobeline		(1) Internal	(1) 3mg (MD) 74	

		from the restriction only medicines	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		form		
		$(2) \mathbf{E} + 1$	9mg (MDD)	
[abalina		(2) External	(1) Equivalant of 2mg of	
Lobeline Hydrochloride		(1) Internal	(1) Equivalent of 3mg of Lobeline (MD)	
			Equivalent of 9mg of Lobeline (MDD)	
		(2) External		
Lobeline Sulphate		(1) Internal	(1) Equivalent of 3mg of Lobeline (MD)	
			Equivalent of 9mg of Lobeline (MDD)	
		(2) External		
]	[^{F69} equivalent of 0.1 per cent Lodoxamide]	treatment of ocular	,	
Lofepramine				
Lofepramine Hydrochloride				
Lofexidine Hydrochloride				
Lomefloxacin Hydrochloride				
Lomustine				
Loperamide Hydrochloride		Treatment of acute		
5		diarrhoea		

. . .

Status: Point in time view as at 31/12/2020. Changes to legislation: There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997. (See end of Document for details)

	1	from the restr only medicine	ictions on the sale and supp es	ply of
Column 1	Column 2	Column 3	Column 4	Column 5
Substance	Maximum strength	Route of administrati use or pharmaceut form		Maximum quantity

[^{F37}Lornoxicam]

[^{F37} Losartan Potassium]
Loxapine Succinate
Lung Surfactant Porcine
Luteinising Hormone
Lymecycline
Lynoestrenol
Lypressin
Lysuride Maleate
Mafenide
Mafenide Acetate
Mafenide Hydrochloride
Mafenide 5.0 per cent Eye drops Propionate
Magnesium
Fluoride
Fluoride Magnesium
Fluoride Magnesium Metrizoate Mandragora
Fluoride Magnesium Metrizoate Mandragora Autumnalis Mannomustine

ŀ	prescription	from the restrict only medicine	ctions on the sale and support of the sale and support	ply of
Substance 1	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form		Column 5 Maximum quantity
Mebendazole		For oral use in the treatment of enterobiasis in adults and in children not less than 2 years	100mg (MD)	Container or package containing not more than 800mg of Mebendazole
Mebeverine Hydrochloride		[^{F72} (a) For the symptomatic relief of irritable bowel syndrome	[^{F72} (a) 135 mg (MD) 405 mg (MDD)]	
		(b) For uses other than the symptomatic relief of irritable bowel syndrome]	[^{F72} (b) 100 mg (MD) 300 mg (MDD)]	
Mebeverine Pamoate				
Mebhydrolin				
Mebhydrolin Napadisylate				
Mecamylamine Hydrochloride				
Mecillinam				
Meclofenoxate Hydrochloride				
Medigoxin				
Medrogestone				
Medroxyproges Acetate	sterone			

		from the restri	ictions on the sale and supp	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity
Mefenamic Acid				
Mefloquine Hydrochlorid	e			
Mefruside				
Megestrol				
Megestrol Acetate				
Meglumine Gadopentetat	e			
Meglumine Iodoxamate				
Meglumine Ioglycamate				
Meglumine Iothalamate				
Meglumine Iotroxate				
Meglumine Ioxaglate				
[^{F36} Meloxicar	n]			
Melphalan				
Melphalan Hydrochlorid	e			
Menotrophin				
Mepenzolate			25mg (MD)	
Bromide			75mg (MDD)	
Mephenesin				
Mephenesin Carbamate				
Mepivacaine Hydrochlorid	e	Any use except ophthalmic use		

		from the restric only medicine	ctions on the sale and sup s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Meptazinol Hydrochloric	le			
Mequitazine				
[^{F25} Mercapta: Bitartrate]	mine			
Mercaptopur	ine			
Mersalyl				
Mersalyl Acid				
Mesalazine				
Mesna				
Mestranol				
Metaraminol Tartrate				
Metergoline				
Metformin Hydrochloric	le			
Methacycline	e			
Methacycline Calcium	e			
Methacycline Hydrochloric				
Methallenoes	stril			
Methicillin Sodium				
Methixene				
Methixene Hydrochloric	le			
Methocarban	nol			
Methocidin		Throat lozenges and throat pastilles		

	prescription	from the restri n only medicine	ctions on the sale and support	vly of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceution form		Column 5 Maximum quantity
Methohexito Sodium	ne			
Methoin				
Methoserpid	ine			
Methotrexate	e			
Methotrexate Sodium	2			
Methotrimep	razine			
Methotrimep Hydrochloric				
Methotrimep Maleate	razine			
Methoxamin Hydrochlorid		Nasal sprays or nasal drops not containing liquid paraffin as a vehicle		
Methsuximic	le			
Methyclothia	zide			
Methyldopa				
Methyldopat Hydrochloric				
Methylephed			30mg (MD)	
Hydrochloric	ie		60mg (MDD)	
Methylpredn	isolone			
Methylpredn Acetate	isolone			
Methylpredn Sodium Succinate	isolone			
Methylthiour	acil			
Methysergide Maleate	e			

	prescription	from the restri	ctions on the sale and suppos	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form		Column 5 Maximum quantity	
Metipranolol					
Metirosine					
Metocloprami Hydrochloride					
Metolazone					
Metoprolol Fumarate					
Metoprolol Succinate					
Metoprolol Tartrate					
Metronidazole	e				
Metronidazole Benzoate	2				
Metyrapone					
Mexiletine Hydrochloride	9				
Mezlocillin Sodium					
Mianserin Hydrochloride	e				
Miconazole		External but in the case of vaginal use only external use for the treatment of vaginal candidiasis			
Miconazole Nitrate		External but in the case of vaginal use only external use for the treatment			

81

		from the restri only medicine	ictions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
		of vaginal candidiasis		
Mifepristone				
Miglitol				
Milrinone				
Milrinone Lactate				
Minocycline				
Minocycline Hydrochlorid	le			
Minoxidil	[^{F73} (1) 2.0 per cent]	[^{F73} (1) External		
	[^{F73} (2) 5.0 per cent	(2) External use for the treatment of alopecia androgenetic in men aged 18 to 65 (but not in women);]	a,	
[^{F21} Mirtazapi	ne]			
Misoprostol				
Mitobronitol				
Mitomycin				
Mitozantrone Hydrochloric				
Mivacurium Chloride				
[^{F46} Mizolasti	ne]			
Moclobemid	e			
[^{F25} Modafinil]			
[^{F22} Moexipril Hydrochloric				

		from the restrictio only medicines	ns on the sale and sup	oply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Co	olumn 4 reatment limitations	Column 5 Maximum quantity
Molgramosti	m			
Molindone Hydrochlorid	e			
Mometasone Furoate				
Moracizine Hydrochlorid	e			
Morazone Hydrochlorid	e			
[^{F21} Moxonidi	ne]			
Mupirocin				
Mupirocin Calcium				
Mustine Hydrochlorid	e			
Nabilone				
Nabumetone				
Nadolol				
Nafarelin Acetate				
Naftidrofuryl Oxalate				
Naftifine Hydrochlorid	e			
Nalbuphine Hydrochlorid	e			
Nalidixic Acid				
Nalorphine Hydrobromid	le			
Naloxone Hydrochlorid	e			
Naltrexone Hydrochlorid	e			

			ctions on the sale and sup	pply of
Column 1 Substance	prescription Column 2 Maximum strength	only medicine Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Naphazoline Hydrochlorid		(1) Nasal sprays or nasal drops not containing liquid paraffin as a vehicle		
	(2) 0.015 per cent	(2) Eye drops		
Naphazoline Nitrate	0.05 per cent	Nasal sprays or nasal drops not containing liquid paraffin as a vehicle		
Naproxen				
Naproxen Sodium				
[^{F25} Naratripta Hydrochlorid				
Natamycin				
[^{F37} Nebivolol Hydrochlorid				
Nedocromil Sodium	[^{F74} 2.0 per cent]	[^{F74} For the prevention, relief and treatment of seasonal and perennial allergic conjunctivitis	5]	[^{F74} Container or package containing not more than 3 ml of medicinal product]
Nefazodone Hydrochlorid	e			
Nefopam Hydrochlorid	e			
Neomycin				

84

	prescription	from the restruction only medicine	ictions on the sale and suppers	ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Neomycin Oleate					
Neomycin Palmitate					
Neomycin Sulphate					
Neomycin Undecanoate					
Neostigmine Bromide					
Neostigmine Methylsulphat	e				
Netilmicin Sulphate					
Nicardipine Hydrochloride					
Nicergoline					
[^{F46} Niceritrol]					
Nicotinic Acid		Any use, except for the treatment of hyperlipidae	600mg (MDD) mia		
Nicoumalone					
Nifedipine					
Nifenazone					
Nikethamide					
[^{F24} Nilutamide]				
Nimodipine					
Niridazole					
[^{F37} Nisoldipine	2]				
Nitrendipine					
Nitrofurantoin					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Nitrofurazone		jorm			
Nizatidine		For the prevention [^{F75} and treatment] of the symptoms of food- related heartburn [^{F75} and meal- induced indigestion] For use in	75mg (MD) [^{F76} 150mg (MDD)] [^{F77} For a maximum period of 14 days]		
Nomifensine		adults and children not less than 16 years			
Maleate					
Noradrenaline					
Noradrenaline Acid Tartrate	:				
Norethisteron	e				
Norethisteron Acetate	2				
Norethisteron Enanthate	2				
Norethynodre	l				
Norfloxacin					
Norgestimate					
Norgestrel					
Nortriptyline Hydrochloride	2				
Noscapine					

		from the restrictions on the sale and su only medicines	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity
Noscapine Hydrochlorid	e		
Novobiocin Calcium			
Novobiocin Sodium			
Nux Vomica Seed			
Nystatin	[^{F78} 3.0 per cent]	[^{F78} External For use in combination with Hydrocortisone of maximum strength 0.5 per cent for intertrigo For use in adults and children not less than 10 years]	[^{F78} Container or package containing not more than 15g of medicinal product]
Octacosactrir	1		
Octreotide			
Oestradiol Oestradiol Benzoate			
Oestradiol Cypionate			
Oestradiol Dipropionate			
Oestradiol Diundecanoa	te		
Oestradiol Enanthate			

	prescription	n only medicin		
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrat use or pharmaceut form	Column 5 Maximum quantity	
Oestradiol Phenylpropie	onate			
Oestradiol Undecanoate	2			
Oestradiol Valerate				
Oestriol				
Oestriol Succinate				
Oestrogenic Substances Conjugated				
Oestrone				
Ofloxacin				
Olsalazine Sodium				
Omeprazole				
[^{F21} Omepraze Magnesium]				
Ondansetron Hydrochlorid				
Orciprenalin Sulphate	e			
Orphenadrin Citrate	e			
Orphenadrin Hydrochlorid				
Ouabain				
Ovarian Gland Dried				
Oxamniquin	e			
Oxantel Embonate				
Oxaprozin				

		from the restruction only medicine	ictions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Oxatomide				
Oxedrine Tartrate				
Oxethazaine			10mg (MD)	Container
			30mg (MDD)	or package containing not more than 400mg of Oxethazaine
Oxitropium Bromide				
Oxolinic Acid				
Oxpentifyllin	ne			
Oxprenolol Hydrochloric	le			
Oxybuprocai Hydrochloric		Non- ophthalmic use		
Oxybutynin Hydrochloric	le			
Oxypertine				
Oxypertine Hydrochloric	le			
Oxyphenbuta	azone			
Oxyphencyc Hydrochloric				
Oxyphenoniu Bromide	ım		5mg (MD) 15mg (MDD)	
Oxytetracycl	ine		/	
Oxytetracycl Calcium				
Oxytetracycl Dihydrate	ine			

			ctions on the sale and suppl	y of
Column 1 Substance	prescription Column 2 Maximum strength	only medicine Column 3 Route of administratiuse or pharmaceutit form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Oxytetracycl Hydrochlorid				
Oxytocin, natural				
Oxytocin, synthetic				
Pancreatin	(1) 21,000 European Pharmacopo units of lipase per capsule	(1) capsules eia		
	(2) 25,000 European Pharmacopo units of lipase per gram	(2) powder eia		
Pancuronium Bromide	1			
[^{F36} Pantopraz Sodium]	zole			
Papaverine		(1) By inhaler		
		(2) Otherwise than by inhaler	(2) 50mg (MD) 150mg (MDD)	
Papaverine Hydrochlorid	le	(1) By inhaler		
		(2) Otherwise	(2) Equivalent of 50mg of Papaverine (MD)	
		than by inhaler	Equivalent of 150mg of Papaverine (MDD)	
[^{F26} Paracetan	nol (1) [^{F79} 25	0mg(1) Non- effervescent tablets and capsules		(1) The quantity sold or supplied in

Exemptions from the restrictions on the sale and supply of prescription only medicines					
Solumn 1 ubstance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity		
	(2) 500 mg	[^{F80} wholly or mainly] for use in children aged less than 12 years (2) Non- effervescent tablets and capsules [^{F81} wholly or mainly] for use in adults and children not less than 12 years	one container or package shall not exceed 32 The quantity of non- effervescent tablets, capsules or a combination of both sold or supplied to a person at any one time shall not exceed 100		
		(3) All preparations other than non- effervescent tablets and capsules	(2) The quantity sold or supplied in one container or package shall not exceed 32 The quantity of non- effervescent tablets, capsules or a		

		from the restriction only medicine	ctions on the sale and sup	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
				combination of both sold or supplied to a person at any one time shall not exceed 100]
Paraldehyde				
Paramethadio	ne			
Paramethason Acetate	ie			
Parathyroid Gland				
Pargyline Hydrochlorid	e			
Paroxetine Hydrochlorid	e			
Pecilocin				
Penamecillin				
Penbutolol Sulphate				
[^{F36} Penciclovi	r]			
Penicillamine				
Penicillamine Hydrochlorid				
Pentamidine Isethionate				
Penthienate Bromide			5mg (MD) 15mg (MDD)	

		from the restric only medicine	ctions on the sale and sup s	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Pentolinium Tartrate				
Perfluamine				
Pergolide Mesylate				
Perhexiline Maleate				
Pericyazine				
Perindopril				
Perindopril Erbumine				
Perphenazine				
Phenacetin 0	0.1 per cent			
Phenazone		External		
Phenazone Salicylate				
Phenbutrazate Hydrochloride				
Phenelzine Sulphate				
Phenethicillin Potassium				
Phenformin Hydrochloride				
Phenglutarimid Hydrochloride	le			
Phenindione				
[^{F82} Phenolphtha	alein.]			
Phenoxybenzar Hydrochloride	nine			
Phenoxymethy	lpenicillin			
Phenoxymethy Calcium	-			

		from the restring only medicine	ictions on the sale and suppers	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Phenoxymethy Potassium	ylpenicillin			
Phenprocoum	on			
Phensuximide				
Phentolamine Hydrochloride	•			
Phentolamine Mesylate				
Phenylbutazor	ne			
Phenylbutazor Sodium	ne			
Phenylpropan		Internal		
Hydrochloride	,	(1) all preparations except prolonged release capsules, nasal sprays and nasal drops	(1) 25mg (MD) 100mg (MDD)	
		(2) prolonged	(2) 50mg (MD)	
		prolonged release capsules	100mg (MDD)	
	(3) 2.0 per cent	(3) nasal sprays and nasal drops		
Phenytoin				
Phenytoin Sodium				
Phthalylsulpha	athiazole			
Physostigmine	e			
Physostigmine Aminoxide Salicylate	2			

	Exemptions	ply of		
Column 1	prescription Column 2	i only medicine Column 3	es Column 4	Column 5
Substance	Maximum strength	Route of administrati use or pharmaceuti form	Treatment limitations ion,	<i>Maximum</i> <i>quantity</i>
Physostigmir Salicylate	ne			
Physostigmir Sulphate	ne			
[^{F24} Phytomer	nadione	Any use except the prevention or treatment of haemorrhagic disorders]	с	
Picrotoxin				
Pilocarpine				
Pilocarpine Hydrochlorid	le			
Pilocarpine Nitrate				
Pimozide				
Pindolol				
Pipenzolate			5mg (MD)	
Bromide			15mg (MDD)	
Piperacillin Sodium				
Piperazine Oestrone Sulphate				
Piperidolate			50mg (MD)	
Hydrochloric	le		150mg (MDD)	
Pipothiazine Palmitate				
Piracetam				
Pirbuterol Acetate				
Pirbuterol Hydrochloric	le			

95

		from the restri only medicine	ctions on the sale and suppl	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrativ use or pharmaceutiv form		Column 5 Maximum quantity
[^{F83} Pirenzepin Dihydrochlon Monohydrate	ide			
Pirenzepine Hydrochlorid	le			
Piretanide				
Piroxicam	0.5 per cent	External For the relief of rheumatic pain, pain of non-serious arthritic conditions and muscular aches, pains and swellings such as strains, sprains and sports injuries For use in adults and children not less than 12 years	For maximum period of 7 days	Container or package containing not more than 30g of medicinal product
[^{F46} Piroxicam Beta- cyclodextrin]				
Pituitary Gland (Whole Dried)		By inhaler		
Pituitary Powdered		By inhaler		

		from the restri only medicine	ctions on the sale and suppose	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceutit form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Pivampicillin	1			
Pivampicillin Hydrochloric				
Pivmecillina	m			
Pivmecillina Hydrochlorid				
Pizotifen				
Pizotifen Malate				
Plicamycin				
Podophylloto	oxin			
Podophyllun	1			
Podophyllun Indian	1			
Podophyllun	-	External		
Resin	cent	Ointment or impregnated plaster		
Poldine			2mg (MD)	
Methylsulph	ate		6mg (MDD)	
Polidexide				
Polyestradio Phosphate	l			
Polymyxin B Sulphate				
Polythiazide				
Poppy Capsule				
Potassium Arsenite	0.0127 per cent			
Potassium Bromide				
Potassium Canrenoate				

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Potassium Clavulanate					
Potassium Perchlorate					
Practolol					
Pralidoxime Chloride					
Pralidoxime Iodide					
Pralidoxime Mesylate					
[^{F25} Pramipexo Hydrochlorid					
Pravastatin Sodium					
Prazosin Hydrochlorid	le				
Prednisolone					
Prednisolone Acetate					
Prednisolone Butylacetate					
Prednisolone Hexanoate					
Prednisolone Metasulphob					
Prednisolone Metasulphob Sodium					
Prednisolone Pivalate					
Prednisolone Sodium Phosphate					

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administration use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Prednisolone Steaglate						
Prednisone						
Prednisone Acetate						
Prenalterol Hydrochloride	e					
Prenylamine Lactate						
Prilocaine Hydrochloride	2	Non- ophthalmic use				
Primidone						
Probenecid						
Probucol						
Procainamide Hydrochloride	2					
Procaine Hydrochloride	2	Non- ophthalmic use				
Procaine Penicillin						
Procarbazine Hydrochloride	2					
Prochlorperaz	ine					
Prochlorperaz Edisylate	ine					
Prochlorperaz Maleate	i ^{ftet} 3mg]	[^{F40} Buccal tablets for the treatment of nausea and vomiting in cases of previously diagnosed migraine	[^{F40} 12mg (MDD)]	[^{F40} Container or package containing not more than 8 tablets]		

		from the restr n only medicine	ictions on the sale and suppers	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
		form only. For use in persons aged 18 years and over.]		
Prochlorperaz Mesylate	zine			
Procyclidine Hydrochlorid	e			
Progesterone				
Prolactin				
Proligestone				
Prolintane Hydrochlorid	e			
Promazine Embonate				
Promazine Hydrochlorid	e			
Propafenone				
Propafenone Hydrochlorid	e			
Propanidid				
Propantheline	2		15mg (MD)	
Bromide			45mg (MDD)	
[^{F37} Propiverin Hydrochlorid				
Propofol				
Propranolol Hydrochlorid	e			
Propylthioura				
Proquazone				
Protamine Sulphate				

		from the restri only medicine	ctions on the sale and supply	v of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity
Prothionamic	le			
Protirelin				
Protriptyline Hydrochloric	le			
Proxymetaca Hydrochloric		Non- ophthalmic use		
Pseudoephedrine Hydrochloride		Internal	(a) In the case of a prolonged release preparation	
			120mg (MD)	
			240mg (MDD)	
			(b) in any other case 60mg (MD)	
			240mg (MDD)	
Pseudoephed	rine		60mg (MD)	
Sulphate			180mg (MDD)	
Pyrantel Embonate		(a) For the treatment of enterobiosis, in adults and children not less than 12 years	(a) 750mg MDD (as a single dose)	(a) Container or package containing not more than 750mg of Pyrantel Embonate
		(b) For the treatment of enterobiosis, in children less than 12 years but not less than 6 years	(b) 500mg MDD (as a single dose)	(b) Container or package containing not more than 750mg of Pyrantel Embonate
		(c) For the treatment of enterobiosis in children less than 6	(c) 250mg MDD (as a single dose)	(c) Container or package containing not more

		from the restric only medicines	ctions on the sale and supp s	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceutio form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
		years but not less than 2 years		than 750mg of Pyrantel Embonate
Pyrantel Tartrate				
Pyrazinamide				
Pyridostigmine Bromide	;			
Pyrimethamine	;			
[^{F37} Quetiapine Fumarate]				
[^{F22} Quinagolide Hydrochloride]				
Quinapril				
[^{F83} Quinapril Hydrochloride]	l			
Quinestradol				
Quinestrol				
Quinethazone				
Quinidine				
Quinidine Bisulphate				
Quinidine Polygalacturon	ate			
Quinidine Sulphate				
Quinine			100mg (MD)	
			300mg (MDD)	
Quinine Bisulphate			Equivalent of 100mg of Quinine (MD)	
			Equivalent of 300mg of Quinine (MDD)	
Quinine Cinchophen			Equivalent of 100mg of Quinine (MD)	
			102	

		from the restrictions on the sale and sup only medicines	ply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity
		Equivalent of 300mg of Quinine (MDD)	
Quinine Dihydrochlo	ride	Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Ethyl		Equivalent of 100mg of Quinine (MD)	
Carbonate		Equivalent of 300mg of Quinine (MDD)	
Quinine Glycerophos	phate	Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Hydrobromio	de	Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Hydrochlorid	le	Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Iodobismuth	ate	Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Phosphate		Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Salicylate		Equivalent of 100mg of Quinine (MD)	
		Equivalent of 300mg of Quinine (MDD)	
Quinine Sulphate		Equivalent of 100mg of Quinine (MD) 103	

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
			Equivalent of 300mg of Quinine (MDD)			
Quinine Tannate			Equivalent of 100mg of Quinine (MD)			
			Equivalent of 300mg of Quinine (MDD)			
Quinine in combination with Urea Hydrochloride	2					
Ramipril						
[^{F21} Ranitidine Bismuth Citrate]						
Ranitidine Hydrochloride	2	For the short term	Equivalent to 75mg of Ranitidine (MD)			
		symptomatic relief of heartburn,	Equivalent to 300mg of Ranitidine (MDD)			
		dyspepsia, indigestion, acid indigestion and hyperacidity [^{F84} or the prevention of these symptoms when	For a maximum period of 14 days			
		associated with consuming food and drink]				
Rauwolfia Serpentina						
Rauwolfia Vomitoria						

	Exemptions from the restrictions on the sale and supply of prescription only medicines					
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity		
Razoxane						
[^{F25} Reboxetine Mesilate]	e					
Remoxipride Hydrochloride	2					
Reproterol Hydrochloride	e					
Rescinnamine						
Reserpine						
Rifabutin						
Rifampicin						
Rifampicin Sodium						
Rifamycin						
[^{F21} Rimexolon	ie]					
Rimiterol Hydrobromide	e					
Risperidone						
Ritodrine Hydrochloride	e					
Rolitetracyclii Nitrate	ne					
[^{F41} Ropinirole Hydrochloride						
Sabadilla						
Salbutamol						
Salbutamol Sulphate						
Salcatonin						
Salcatonin Acetate						
Salmefamol						

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Salmeterol Xinafoate					
Salsalate					
Saralasin Acetate					
Selegiline Hydrochlorid	e				
Semisodium Valproate					
[^{F25} Sertindole]				
[^{F21} Sertraline Hydrochlorid	e]				
Serum Gonadotrophi	in				
[^{F21} Sevoflurar	ne]				
Silver Sulphadiazine	e				
Simvastatin					
Sissomicin					
Sissomicin Sulphate					
Snake Venoms					
Sodium Acetrizoate					
Sodium Aminosalicyl	ate				
Sodium Antimonylglu	iconate				
Sodium Arsanilate					
Sodium Arsenate					

		from the restrictions on the sale only medicines	e and supply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limit administration, use or pharmaceutical form	Column 5 ations Maximum quantity
Sodium Arsenite	0.013 per cent		
Sodium Bromide			
Sodium Clodronate			
Sodium Cromoglyca	te	(a) For nasal admistration	
	(b) 2.0 per cent	(b) For the treatment of acute seasonal allergic conjunctivitis [^{F85} or perennial allergic conjunctivitis]	(b) Container or package containing not more than 10ml of medicinal product
		In the form of aqueous eye drops	
	(c) 4.0 per cent	(c) For the treatment of acute seasonal allergic conjunctivitis	(c) Container or package containing not more than 5g of medicinal
		In the form of an eye ointment	product
Sodium Ethacrynate			
Sodium Fluoride	(1) 0.33 per cent	(1) Dentifrices	
		(2) Other preparations for use in the prevention	
		107	

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations on,	Column 5 Maximum quantity	
		of dental caries			
		In the form of			
		(a) tablets or drops	(a) 2.2 mg (MDD)		
	(b) 0.2 per cent	(b) mouth rinses other than those for daily use			
	(c) 0.05 per cent	(c) mouth rinses for daily use			
Sodium Fusidate					
Sodium Metrizoate					
Sodium Monofluoro	1.14 per phæspthate	Dentrifrice			
Sodium Oxidronate					
Sodium Stiboglucon	ate				
Sodium Valproate					
Somatorelin Acetate					
Sotalol Hydrochlori	de				
[^{F22} Sparfloxa	acin]				
Spectinomy	cin				
Spectinomy Hydrochlori					
Spiramycin					
Spiramycin Adipate					
			100		

		from the restrictions on the sale and superior of the sale and superior only medicines	pply of
Column 1 Substance	Column 2 Maximum strength	Column 3 Column 4 Route of Treatment limitations administration, use or pharmaceutical form	Column 5 Maximum quantity
Spironolacto	one		
Stannous Fluoride	([^{F86} 1]) 0.62 per cent	([^{F86} 1]) Dentifrice	
	[^{F86} (2) 0.4 per]	[^{F86} (2) Dental gels for use in the prevention and treatment of dental caries and decalcification of the teeth]	
Stilboestrol			
Stilboestrol Dipropionate	e		
Streptodorna	ise	External	
Streptokinas	e	External	
Streptomycin	n		
Streptomycin Sulphate	n		
Strychnine			
Strychnine Arsenate			
Strychnine Hydrochlorid	de		
[^{F24} Strychnin Nitrate]	ie		
Styramate			
Succinylsulp	ohathiazole		
Sucralfate			
Sulbactam Sodium			
Sulbenicillin	l		

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	prescription Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Sulbenicillin Sodium				
Sulconazole Nitrate		External (except vaginal)		
[^{F24} Sulfabenz	zamide]			
Sulfacytine				
Sulfadoxine				
Sulfamerazir	ne			
Sulfamerazir Sodium	ie			
Sulfametopy	razine			
Sulfamonom	ethoxine			
Sulindac				
Sulphacetam				
Sulphacetam Sodium	ide			
Sulphadiazin				
Sulphadiazin Sodium	e			
Sulphadimet	hoxine			
Sulphadimid				
Sulphadimid Sodium	ine			
Sulphafurazo	ole			
Sulphafurazo Diethanolam				
Sulphaguanio	dine			
Sulphaloxic Acid				
Sulphamethiz	zole			
Sulphametho	oxazole			

	prescription	only medicine		
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 5 Maximum quantity	
Sulphametho	xydiazine			
Sulphametho	xypyridazine			
Sulphametho Sodium	xypyridazine			
Sulphamoxol	e			
Sulphanilami	de			
Sulphaphena	zole			
Sulphapyridi	ne			
Sulphapyridi Sodium	ne			
Sulphasalazii	ne			
Sulphathiazo	le			
Sulphathiazo Sodium	le			
Sulphaurea				
Sulphinpyraz	zone			
Sulpiride				
Sultamicillin				
Sultamicillin Tosylate				
Sulthiame				
Sumatriptan Succinate				
Suprofen				
Suxamethoni Bromide	um			
Suxamethoni Chloride	um			
Suxethonium Bromide	l			
[^{F37} Tacalcitol Monohydrate				

<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratic use or pharmaceutic form	Column 4 Treatment limitations on,	Column 5 Maximum quantity
Tacrine Hydrochlorid	e			
Talampicillin				
Talampicillin Hydrochlorid				
Talampicillin Napsylate				
Tamoxifen				
Tamoxifen Citrate				
[^{F36} Tamsulosi Hydrochlorid				
[^{F21} Tazaroten	e]			
Tazobactam Sodium				
Teicoplanin				
[^{F25} Temocapr Hydrochlorid				
Temocillin Sodium				
Tenoxicam				
Terazosin Hydrochlorid	e			
Terbinafine	[^{F87} 1.0 per cent]	[^{F88} External use for the treatment of tinea pedis, tinea cruris and tinea corporis. In the form of a gel]		[^{F89} Container or package containing not more than 30 grams of medicinal product]
[^{F90} Terbinafin Hydrochlorid		([^{F91} 1]) [^{F92} Preparation other than spray	ns, 112	([^{F91} 1]) [^{F90} Container or package containing

	<i>Exemptions from the restrictions on the sale and supply of prescription only medicines</i>				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
		<i>form</i> solutions, for][^{F90} extern use for the treatment of tinea pedis and tinea cruris]		not more than 15 g of medicinal product.]	
		[^{F93} (2) Spray solutions for external use for the treatment of tinea corporis, tinea cruris and tinea pedis]		[^{F93} (2) Container containing not more than 30ml of medicinal product]	
Terbutaline					
Terbutaline Sulphate					
Terfenadine			F94	F94	
Terlipressin					
Terodiline Hydrochlorid	e				
[^{F25} Testostero	ne]				
Tetrabenazine	e				
Tetracosactrii	1				
Tetracosactrii Acetate	1				
Tetracycline					
Tetracycline Hydrochlorid	e				
Tetracycline Phosphate Complex					
Tetroxoprim					

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratiuse or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Thallium Acetate					
Thallous Chloride					
Thiabendazo	le				
Thiambutosi	ne				
Thiethylpera: Malate	zine				
Thiethylpera: Maleate	zine				
Thiocarlide					
Thioguanine					
Thiopentone Sodium					
Thiopropazat Hydrochloric					
Thioproperaz Mesylate	zine				
Thioridazine					
Thioridazine Hydrochlorid	le				
Thiosinamine	e				
Thiotepa					
Thiothixene					
Thiouracil					
Thymoxamir Hydrochloric					
Thyroid					
Thyrotrophin	l				
Thyroxine Sodium					
Tiamulin Fumarate					

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 C	'olumn 4 reatment limitations	Column 5 Maximum quantity	
Tiaprofenic Acid					
Tibolone					
Ticarcillin Sodium					
[^{F36} Ticlopidin Hydrochlorid					
Tigloidine Hydrobromid	le				
[^{F36} Tiludrona Disodium]	te				
Timolol Maleate					
Tinidazole					
Tinzaparin					
Tioconazole	(1) 2.0 per cent	(1) External (except vaginal)			
		(2) Vaginal for treatment of vaginal candidiasis			
[^{F22} Tizanidine Hydrochlorid					
Tobramycin					
Tobramycin Sulphate					
Tocainide Hydrochlorid	e				
Tofenacin Hydrochlorid	e				
Tolazamide					
Tolazoline Hydrochlorid	e	External			

Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity
Tolbutamide				
Tolbutamide Sodium				
Tolfenamic Acid				
Tolmetin Sodium				
[^{F21} Topiramat	te]			
[^{F46} Torasemic				
[^{F36} Toremifer	ne]			
Tramadol Hydrochlorid	le			
Trandolapril				
Tranexamic Acid				
Tranylcypror Sulphate	nine			
Trazodone Hydrochloric	le			
Treosulfan				
Tretinoin				
Triamcinolor	ne			
Triamcinolor Acetonide	nq ^{F95} (1)] 0.1 per cent	[^{F95} (1)] For the treatment of common mouth ulcers		[^{F95} (1)] Container or package containing not more than 5g of medicinal product
		[^{F96} (2) In the form of a non- pressurised nasal spray, for the	[^{F96} (2) 110mcg per nostril (MD) 110mcg per nostril (MDD) 116	[^{F96} Container or package containing not more than 3.575mg of

	prescription	from the restruction from the restruction from the restruction only medicine	ictions on the sale and supples	y of
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut		Column 5 Maximum quantity
		form	icui	
		treatment of symptoms of seasonal allergic rhinitis in persons aged 18 years and over]	For a maximum period of 3 months]	Triamcinolone Acetonide]
Triamcinolor Diacetate	ne			
Triamcinolor Hexacetonide				
Triamterene				
Tribavirin				
Triclofos Sodium				
Trientine Dihydrochlor	ride			
Trifluoperazi	ne			
Trifluoperazi Hydrochlorid				
Trifluperidol				
Trifluperidol Hydrochlorid				
Trilostane				
Trimeprazine	e			
Trimeprazine Tartrate	2			
Trimetaphan Camsylate				
Trimetazidin	e			
Trimetazidin Hydrochlorid				
Trimethoprin	n			

		Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administratio use or pharmaceuti form	Column 4 Treatment limitations on,	Column 5 Maximum quantity		
Trimipramine Maleate	2					
Trimipramine Mesylate	2					
Tropicamide						
Tropisetron Hydrochlorid	e					
Troxidone						
L-		(1) Oral				
Tryptophan		Dietary supplementat	ion			
		(2) External				
Tubocurarine Chloride						
Tulobuterol						
Tulobuterol Hydrochlorid	e					
Tyrothricin		Throat lozenges or throat pastilles				
Uramustine						
Urea Stibamine						
Urethane						
Uridine 5'- triphosphate						
Urofollitroph	in					
Urokinase						
Ursodeoxych Acid	oic					
Vaccine: Bacillus Salmonella Typhi						

Exemptions from the restrictions on the sale and supply of prescription only medicines				ply of	
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Column 4 Treatment limitations ion,	Column 5 Maximum quantity	
Vaccine: Poliomyelitis (Oral)	5				
[^{F22} Valaciclov Hydrochloric					
Valproic Acid					
[^{F25} Valsartan]					
Vancomycin Hydrochlorid	le				
Vasopressin					
Vasopressin Tannate					
Vecuronium Bromide					
[^{F22} Venlafaxi Hydrochloric					
Verapamil Hydrochlorid	le				
Veratrine					
Veratrum, Green					
Veratrum, White					
Vidarabine					
Vigabatrin					
Viloxazine Hydrochloric	le				
Vinblastine Sulphate					
Vincristine Sulphate					
Vindesine Sulphate					

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form		Column 5 Maximum quantity	
Viomycin Pantothenate					
Viomycin Sulphate					
Vitamin A		(1) Internal	(1) 7,500iu (2,250mcg Retinol equivalent) (MDD)		
		(2) External			
Vitamin A Acetate		(1) Internal	(1) Equivalent to 7,500iuVitamin A (2,250mcgRetinol equivalent)(MDD)		
		(2) External			
Vitamin A Palmitate		(1) Internal	(1) Equivalent to 7,500iuVitamin A (2,250mcgRetinol equivalent)(MDD)		
		(2) External			
Warfarin					
Warfarin Sodium					
Xamoterol Fumarate					
Xipamide					
Yohimbine Hydrochloride	•				
[^{F22} Zalcitabine	;]				
Zidovudine					
Zimeldine Hydrochloride	;				
Zolpidem Tartrate					
Zomepirac Sodium					
Zopiclone					

	Exemptions from the restrictions on the sale and supply of prescription only medicines				
Column 1 Substance	Column 2 Maximum strength	Column 3 Route of administrati use or pharmaceut form	Treatment limitations fon,	Column 5 Maximum quantity	
Zuclopenthix Acetate	col				
Zuclopenthix Decanoate	col				
Zuclopenthiz Hydrochlorid					

Textu	al Amendments
F21	Words in Sch. 1 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendmen
	Order 2000 (S.I. 2000/1917), arts. 1(1), 3(c)
F22	Words in Sch. 1 inserted (19.1.2000) by The Prescription Only Medicines (Human Use) Amendment
	(No. 2) Order 1999 (S.I. 1999/3463), arts. 1(1), 2(c)
F23	Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment
	Order 2001 (S.I. 2001/2777), arts. 1(1), 3(a)
F24	Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment
	(No. 3) Order 1998 (S.I. 1998/2081), art. 1(1), Sch.
F25	Sch. 1 entries inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order
	2001 (S.I. 2001/2777), arts. 1(1), 3(g)
F26	Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendmen
	Order 1997 (S.I. 1997/2044), art. 1(1), Sch. 1
F27	Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendmen
	Order 1999 (S.I. 1999/1044), arts. 1(1), 2(a)
F28	Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendmen
	(No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(a)
F29	Sch. 1: entries renumbered (22.4.1999) by The Prescription Only Medicines (Human Use) Amendmen
	Order 1999 (S.I. 1999/1044), arts. 1(1), 2(a)
F30	Words in Sch. 1 omitted (16.9.1998) by virtue of The Prescription Only Medicines (Human Use)
E 21	Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(b)
F31	Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendmen
E22	(No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(a)
F32	Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendmen
F33	(No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(a) Word in Sch. 1 substituted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendmen
г ээ	Order 1999 (S.I. 1999/1044), arts. 1(1), 2(b)
F34	Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendmen
Г 34	(No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(c)(ii)
F35	Words in Sch. 1 substituted (16.9.1998) by virtue of The Prescription Only Medicines (Human Use
г 33	Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), 3(c)(i)
F36	Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendmen
r50	(No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(h)
	(110. 2) Order 2000 (0.1. 2000/2077), arts. 1(1), 4(1)

- **F37** Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), **2(e)**
- **F38** Word in Sch. 1 substituted (16.9.1997) by The Prescription Only Medicines (Human Use) Amendment Order 1997 (S.I. 1997/2044), arts. 1(1), **2(a)**
- F39 Words in Sch. 1 revoked (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(a)
- **F40** Sch. 1 entries inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(f)**
- F41 Sch. 1 entries inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(e)
- F42 Sch. 1 entries inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(b)
- F43 Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(a)
- F44 Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(d)**
- F45 Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(c)
- F46 Words in Sch. 1 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, 3(e)(i)
- F47 Word in Sch. 1 substituted (19.1.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1999 (S.I. 1999/3463), arts. 1(1), 2(a)
- **F48** Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(e)**
- **F49** Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(b)**
- **F50** Words in Sch. 1 substituted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(f)(i)**
- **F51** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(f)(ii)**
- **F52** Words in Sch. 1 omitted (16.9.1998) by virtue of The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(f)(iii)**
- **F53** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(b)(i)**
- **F54** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(b)(ii)**
- F55 Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(b)(iii)
- **F56** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(b)(iv)**
- **F57** Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), **2(c)**
- **F58** Sch. 1: entries renumbered (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), **2(c)**
- **F59** Words in Sch. 1 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, **3(a)**
- **F60** Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(c)**
- **F61** Words in Sch. 1 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **3(a)**
- **F62** Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(d)

- **F63** Word in Sch. 1 inserted (13.8.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, **3(e)(ii)**
- F64 Word in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(g)(ii)**
- **F65** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(g)(i)**
- **F66** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(g)(iii)**
- F67 Words in Sch. 1 inserted (19.1.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1999 (S.I. 1999/3463), arts. 1(1), **2(b)**
- **F68** Sch. 1 entries inserted (1.1.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 2000 (S.I. 2000/3231), arts. 1(1), **2**
- **F69** Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(e)(i)
- **F70** Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(e)(ii)
- F71 Words in Sch. 1 revoked (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), 2(c)
- **F72** Words in Sch. 1 substituted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, **3(b)**
- F73 Words in Sch. 1 substituted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(b)
- **F74** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 3) Order 1998 (S.I. 1998/2081), arts. 1(1), **3(h)**
- F75 Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(c)(i)
- **F76** Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(c)(ii)**
- F77 Words in Sch. 1 substituted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), 2(c)(iii)
- **F78** Words in Sch. 1 inserted (22.4.1999) by The Prescription Only Medicines (Human Use) Amendment Order 1999 (S.I. 1999/1044), arts. 1(1), **2(d)**
- **F79** Words in Sch. 1 substituted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(f)(i)
- **F80** Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(f)(ii)
- **F81** Words in Sch. 1 inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(f)(iii)
- **F82** Words in Sch. 1 inserted (16.9.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(d)(ii)**
- **F83** Words in Sch. 1 inserted (1.6.1998) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 1998 (S.I. 1998/1178), arts. 1(1), **2(d)(i)**
- **F84** Words in Sch. 1 added (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, **3(c)**
- **F85** Words in Sch. 1 inserted (13.2.1998) by The Prescription Only Medicines (Human Use) Amendment Order 1998 (S.I. 1998/108), arts. 1, **3(d)**
- **F86** Sch. 1: entries renumbered (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(d)**
- **F87** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(d)(i)**
- **F88** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(d)(ii)**

- **F89** Words in Sch. 1 inserted (31.12.2001) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2001 (S.I. 2001/3942), arts. 1(1), **2(d)(iii)**
- **F90** Words in Sch. 1 inserted (9.8.2000) by The Prescription Only Medicines (Human Use) Amendment Order 2000 (S.I. 2000/1917), arts. 1(1), **3(b)**
- **F91** Sch. 1: entries renumbered (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(e)**
- **F92** Words in Sch. 1 inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(e)**
- **F93** Sch. 1 entries inserted (24.8.2001) by The Prescription Only Medicines (Human Use) Amendment Order 2001 (S.I. 2001/2777), arts. 1(1), **3(e)**
- **F94** Words in Sch. 1 omitted (16.9.1997) by virtue of The Prescription Only Medicines (Human Use) Amendment Order 1997 (S.I. 1997/2044), arts. 1(1), **2(b)**
- **F95** Sch. 1 entries re-numbered (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), 4(g)
- **F96** Sch. 1 entries inserted (16.11.2000) by The Prescription Only Medicines (Human Use) Amendment (No. 2) Order 2000 (S.I. 2000/2899), arts. 1(1), **4(g)**

[^{F97}SCHEDULE 2

Article 10(1)

SUBSTANCES WHICH MAY BE EXCLUDED FROM THE CLASS OF PRESCRIPTION ONLY MEDICINES AT HIGH DILUTION

Textual Amendments

F97 Sch. 2 substituted (1.5.2006) by The Medicines for Human Use (Prescribing) (Miscellaneous Amendments) Order 2006 (S.I. 2006/915), arts. 1(1), **12**

Codeine and its salts

Dihydrocodeine and its salts

Ethylmorphine and its salts

Morphine and its salts

Medicinal Opium

Pholcodine and its salts]

^{F98}SCHEDULE 3

Article 2(b)

DESCRIPTIONS AND CLASSES OF PRESCRIPTION ONLY MEDICINES IN RELATION TO WHICH community practitioner nurse prescribers ARE APPROPRIATE PRACTITIONERS

Textual Amendments

F98 Schs. 3-7 revoked (14.8.2012) by The Human Medicines Regulations 2012 (S.I. 2012/1916), reg. 1(2),
 Sch. 35 (with Sch. 32)

^{F98}SCHEDULE 3A

CONTROLLED DRUGS WHICH MAY BE PRESCRIBED, ADMINISTERED OR DIRECTED FOR ADMINISTRATION BY NURSE INDEPENDENT PRESCRIBERS AND CONDITIONS FOR SUCH PRESCRIPTION OR ADMINISTRATION

^{F98}SCHEDULE 3B

Regulation 3B(3)(a)(iii)

PARTICULARS FOR CLINICAL MANAGEMENT PLANS

^{F98}SCHEDULE 4

Article 8(4)(c)

SUBSTANCES NOT TO BE CONTAINED IN A PRESCRIPTION ONLY MEDICINE SOLD OR SUPPLIED UNDER THE EXEMPTION CONFERRED BY ARTICLE 8(3)

^{F98}SCHEDULE 5

Article 11(1)(a)

EXEMPTION FOR CERTAIN PERSONS FROM SECTION 58(2) OF THE ACT

PART I

EXEMPTION FROM RESTRICTIONS ON SALE OR SUPPLY

Article 11(1)(b)

PART II

EXEMPTIONS FROM THE RESTRICTION ON SUPPLY

Article 11(2)

Article 3A

^{F98}PART III

EXEMPTIONS FROM RESTRICTION ON ADMINISTRATION Column 1

^{F98}SCHEDULE 6

Article 16(1)

ORDERS REVOKED

^{F98}SCHEDULE 7

Articles 12A to 12C

EXPLANATORY NOTE

(This note is not part of the Order)

This Order consolidates with amendments the Medicines (Products Other Than Veterinary Drugs) (Prescription Only) Order 1983 as amended. That Order and the Orders amending it ("the 1983 Order as amended") are revoked by article 16 and Schedule 6.

This Order specifies the descriptions and classes of prescription only medicines (i.e. medicinal products which, subject to exemptions, may be sold or supplied by retail only in accordance with a prescription given by an appropriate practitioner and which may be administered only by or in accordance with the directions of such a practitioner). Many medicinal products are included in a class of such medicines by reason of the substances contained in them (*see*Schedule 1) but others are included because of other criteria, such as their method of administration (*see*article 3). In many cases the provisions of the Act apply subject to exemptions (*see*articles 4 and 5 to 13 and Schedule 1).

The principal amendments relate to those medicines in respect of which marketing authorizations have been granted by the European Community. They include as prescription only medicines those medicines in respect of which such an authorization has been granted which classifies a medicine as being subject to medical prescription (article 3(f)). They exclude from the class of prescription only medicines those medicines in respect of which such an authorization provides for supply which is not subject to medical prescription (article 6(3)).

The differences between this Order and the 1983 Order as amended are in the main technical changes concerning the location of provisions such as the division of material in Schedule 1 to the 1983 Order as amended between the new Schedules 1 and 2. But within the new Schedule 1 there are changes which relate to-

(a) the deletion from Column 1 of substances which are no longer used in those medicinal products which are on the market;

- (b) the use of current names for the substances which are specified in that Column where their names have changed;
- (c) the incorporation in that Schedule of provisions from article 4 of, and Part IV of Schedule 1 to, the 1983 Order as amended so that they may be found more easily;
- (d) a change in the legal base for the entries in Columns 2 to 4 so that those entries now form the criteria for exemptions from the sale or supply requirements of section 58(2) of the Medicines Act 1968 instead of the criteria for excluding medicinal products from the class of prescription only medicines (*see also*article 5);
- (e) the introduction of a fifth Column which specifies the maximum pack sizes to which exemptions apply.

As this order will impose no additional costs to business a compliance cost assessment has not been prepared.

Status:

Point in time view as at 31/12/2020.

Changes to legislation:

There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997.